|
humans |
65 |
|
atrial fibrillation |
59 |
|
female |
44 |
|
heart failure |
43 |
|
coronary artery disease |
42 |
|
male |
40 |
|
middle aged |
38 |
|
myocardial infarction |
38 |
|
ischemic stroke |
36 |
|
aged |
35 |
|
adult |
32 |
|
animals |
32 |
|
type 2 diabetes mellitus |
32 |
|
endothelial progenitor cells |
31 |
|
type 2 diabetes |
28 |
|
hypertension |
27 |
|
medical sciences |
26 |
|
bnt162b2 |
25 |
|
coronavac |
25 |
|
covid-19 vaccine |
25 |
|
induced pluripotent stem cells |
25 |
|
secondary prevention |
25 |
|
vitamin d |
25 |
|
mortality |
23 |
|
mice |
22 |
|
recurrence |
22 |
|
treatment outcome |
22 |
|
cardiovascular diseases |
21 |
|
chinese |
21 |
|
obesity |
21 |
|
risk factors |
21 |
|
atherosclerosis |
20 |
|
body mass index |
19 |
|
mendelian randomization |
19 |
|
sars-cov-2 |
19 |
|
tricuspid annuloplasty |
19 |
|
self-controlled case series |
18 |
|
blood pressure |
17 |
|
cardiomyocytes |
17 |
|
major adverse cardiovascular events |
17 |
|
prospective studies |
17 |
|
stroke |
17 |
|
aged, 80 and over |
16 |
|
endothelial function |
16 |
|
cells, cultured |
15 |
|
covid-19 |
15 |
|
cross-sectional studies |
15 |
|
echocardiography |
15 |
|
endothelial dysfunction |
15 |
|
inflammation |
15 |
|
mesenchymal stem cells |
15 |
|
prognosis |
15 |
|
rheumatoid arthritis |
15 |
|
risk prediction |
15 |
|
carotid intima-media thickness |
14 |
|
embryonic stem cells |
14 |
|
follow-up studies |
14 |
|
incidence |
14 |
|
cardiovascular magnetic resonance |
13 |
|
coronary heart disease |
13 |
|
diabetes mellitus |
13 |
|
human induced pluripotent stem cells |
13 |
|
lipocalin-2 |
13 |
|
25-hydroxyvitamin d |
12 |
|
age factors |
12 |
|
cardiomyopathy |
12 |
|
case-control studies |
12 |
|
endothelial cells |
12 |
|
hong kong |
12 |
|
rna, messenger - metabolism |
12 |
|
stem cells |
12 |
|
adverse outcome |
11 |
|
cardiac function |
11 |
|
cell line |
11 |
|
chemicals and cas registry numbers |
11 |
|
double-blind method |
11 |
|
fatty liver disease |
11 |
|
flow cytometry |
11 |
|
hypercholesterolemia |
11 |
|
mafld (metabolic associated fatty liver disease) |
11 |
|
myocardium - metabolism |
11 |
|
outcomes |
11 |
|
overweight |
11 |
|
population based study |
11 |
|
proarrhythmias |
11 |
|
swine |
11 |
|
time factors |
11 |
|
trimetazidine |
11 |
|
adipocyte |
10 |
|
b-type natriuretic peptide |
10 |
|
blood pressure variability |
10 |
|
bradykinin |
10 |
|
cardiac differentiation |
10 |
|
cardiac troponin |
10 |
|
cardiovascular disease |
10 |
|
cell differentiation |
10 |
|
disease models, animal |
10 |
|
exome chip |
10 |
|
fibroblast growth factor |
10 |
|
gastrointestinal haemorrhage |
10 |
|
genetic polymorphism |
10 |
|
inactivated vaccine |
10 |
|
incident cvd |
10 |
|
long covid |
10 |
|
omicron |
10 |
|
post-covid cvd |
10 |
|
risk factor |
10 |
|
safety |
10 |
|
sex difference |
10 |
|
stem cells - physiology |
10 |
|
time in therapeutic range |
10 |
|
vascular endothelial growth factor a - metabolism |
10 |
|
vascular function |
10 |
|
vitamin d-binding protein |
10 |
|
adipokines |
9 |
|
advanced glycation end-products |
9 |
|
angiogenesis |
9 |
|
arrhythmia |
9 |
|
asian-specific |
9 |
|
berberine |
9 |
|
biological markers - blood |
9 |
|
calcium - metabolism |
9 |
|
cell differentiation - drug effects |
9 |
|
cha2ds2-vasc |
9 |
|
chads2 |
9 |
|
chronic kidney disease |
9 |
|
embryonic stem cells - cytology |
9 |
|
exome-chip association analysis |
9 |
|
garlic |
9 |
|
gene expression |
9 |
|
intracranial hemorrhage |
9 |
|
ischemic heart disease |
9 |
|
magnetic resonance imaging - methods |
9 |
|
myocardium - cytology - metabolism |
9 |
|
osteoporosis |
9 |
|
outcome |
9 |
|
pax4 |
9 |
|
prevalence |
9 |
|
retrospective studies |
9 |
|
sex disparity |
9 |
|
spinal cord stimulation |
9 |
|
statin |
9 |
|
tricuspid regurgitation |
9 |
|
vaccine safety |
9 |
|
young-onset ischemic stroke |
9 |
|
4d flow |
8 |
|
acute coronary syndrome |
8 |
|
adipokine |
8 |
|
adiponectin - blood - genetics |
8 |
|
aging, premature - genetics |
8 |
|
asian continental ancestry group - genetics |
8 |
|
asian continental ancestry group - statistics and numerical data |
8 |
|
blood pressure - genetics |
8 |
|
bone marrow cells - physiology - radiation effects |
8 |
|
cardiology |
8 |
|
cardiovascular and cerebrovascular diseases |
8 |
|
catheter ablation |
8 |
|
cell aging - genetics |
8 |
|
cell count |
8 |
|
cell movement - drug effects |
8 |
|
chromosomal proteins, non-histone |
8 |
|
chromosome aberrations |
8 |
|
cirrhosis |
8 |
|
cohort studies |
8 |
|
cytokines |
8 |
|
direct flow |
8 |
|
dna - genetics |
8 |
|
dna damage - genetics |
8 |
|
dna repair - physiology |
8 |
|
dna-binding proteins - genetics - metabolism |
8 |
|
dose-response relationship, drug |
8 |
|
embryonic stem cell |
8 |
|
embryonic stem cells - cytology - drug effects - transplantation |
8 |
|
embryonic stem cells - cytology - metabolism |
8 |
|
endothelial cells - pathology |
8 |
|
endothelial progenitor cell |
8 |
|
endothelium, vascular - physiopathology |
8 |
|
ferric compounds - adverse effects |
8 |
|
fibroblasts - pathology - radiation effects |
8 |
|
gamma rays |
8 |
|
genomic instability |
8 |
|
green fluorescent proteins - analysis - biosynthesis |
8 |
|
hfpef |
8 |
|
high-sensitivity troponin i |
8 |
|
histones - genetics - metabolism - radiation effects |
8 |
|
hypertension - blood - genetics |
8 |
|
imaging |
8 |
|
intracellular signaling peptides and proteins - genetics - metabolism |
8 |
|
intracranial hemorrhages |
8 |
|
intraventricular flow |
8 |
|
ischemia |
8 |
|
lamin type a - genetics - metabolism |
8 |
|
lipids |
8 |
|
lipotoxicity |
8 |
|
liver transplantation |
8 |
|
long qt syndrome |
8 |
|
membrane proteins - genetics - metabolism |
8 |
|
metalloendopeptidases - genetics - metabolism |
8 |
|
mice, mutant strains |
8 |
|
multi-detector computed tomography |
8 |
|
myocarditis |
8 |
|
myocytes, cardiac - cytology - drug effects |
8 |
|
nanoparticles - adverse effects |
8 |
|
nuclear proteins - genetics - metabolism |
8 |
|
pacemaker |
8 |
|
pacing |
8 |
|
phosphoproteins - genetics - metabolism |
8 |
|
protein precursors - genetics - metabolism |
8 |
|
rad51 recombinase |
8 |
|
residual volume |
8 |
|
signal transduction |
8 |
|
staining and labeling - methods |
8 |
|
stem cells - pathology |
8 |
|
superparamagnetic iron oxide |
8 |
|
swine, miniature |
8 |
|
trs 2°p |
8 |
|
valvular surgery |
8 |
|
vascular markers |
8 |
|
vascular markers of atherosclerosis |
8 |
|
ablation |
7 |
|
adherence |
7 |
|
adipocytes - metabolism - pathology |
7 |
|
ankle brachial index |
7 |
|
anoxia - metabolism |
7 |
|
antigens, differentiation - biosynthesis |
7 |
|
antimutagenic agents - pharmacology |
7 |
|
apoptosis |
7 |
|
arrhythmias, cardiac - etiology |
7 |
|
arterial calcification |
7 |
|
arterial stiffness |
7 |
|
arthritisosteogenesis |
7 |
|
barriers |
7 |
|
biology |
7 |
|
bleeding |
7 |
|
blood flow velocity |
7 |
|
bone–vascular axis |
7 |
|
brachial artery - physiopathology |
7 |
|
brain ischemia - blood - diagnosis - mortality |
7 |
|
calcification |
7 |
|
calcium signaling |
7 |
|
cardio-oncology |
7 |
|
cardiovascular diseases - etiology |
7 |
|
cha2ds2-vasc score |
7 |
|
chads2 score |
7 |
|
circulating endothelial progenitor cells |
7 |
|
cobalt - pharmacology |
7 |
|
conduction disorders |
7 |
|
cytokines - biosynthesis |
7 |
|
dietary supplements |
7 |
|
dilated cardiomyopathy |
7 |
|
directed differentiation |
7 |
|
drug repositioning |
7 |
|
electric countershock |
7 |
|
electrocardiography |
7 |
|
electrophysiology |
7 |
|
embryonic stem cells - transplantation |
7 |
|
endothelium, vascular - drug effects - physiology |
7 |
|
endothelium, vascular - drug effects - physiopathology |
7 |
|
epidemiology |
7 |
|
fatty acid-binding proteins - blood |
7 |
|
focus group |
7 |
|
heart |
7 |
|
heart - physiology |
7 |
|
heart rate |
7 |
|
homeostasis - drug effects |
7 |
|
human embryonic stem cells |
7 |
|
hypoxia |
7 |
|
hypoxia inducible factor-1α |
7 |
|
hypoxia-inducible factor 1, alpha subunit - biosynthesis |
7 |
|
intervertebral disc disease |
7 |
|
ischaemic heart disease |
7 |
|
isoflavone |
7 |
|
lacunar infarct |
7 |
|
left ventricular function |
7 |
|
lipid-lowering agents |
7 |
|
lung cancer |
7 |
|
metabolic re-programming |
7 |
|
models, biological |
7 |
|
myocardial infarction - pathology - physiopathology - surgery |
7 |
|
myocardial injury |
7 |
|
myocytes, cardiac - transplantation |
7 |
|
notochord-like cells (ncls) |
7 |
|
nucleus pulposus (np)-like cells |
7 |
|
obstructive sleep apnea |
7 |
|
organ specificity - drug effects |
7 |
|
osteocalcin |
7 |
|
osteogenic endothelial progenitor cells |
7 |
|
percutaneous coronary intervention |
7 |
|
peripheral artery disease |
7 |
|
peritoneal dialysis |
7 |
|
pleiotropic effects |
7 |
|
pr prolongation |
7 |
|
preferences |
7 |
|
psoriasis |
7 |
|
pulmonary hypertension |
7 |
|
questionnaires |
7 |
|
registries |
7 |
|
review |
7 |
|
rheumatoid |
7 |
|
sarcoplasmic reticulum function |
7 |
|
sex factors |
7 |
|
species index: animalia |
7 |
|
statin therapy |
7 |
|
stem cell transplantation - adverse effects |
7 |
|
stroke - blood - diagnosis - mortality |
7 |
|
systemic lupus erythematosus |
7 |
|
troponin t - biosynthesis |
7 |
|
up-regulation |
7 |
|
valvular heart disease |
7 |
|
vascular resistance |
7 |
|
vasodilation |
7 |
|
ventricular dysfunction, left - pathology |
7 |
|
ventricular remodeling |
7 |
|
ventricular remodeling - physiology |
7 |
|
adverse cardiovascular events |
6 |
|
adverse cardiovascular outcomes |
6 |
|
af |
6 |
|
aging - immunology - metabolism |
6 |
|
animal experiment |
6 |
|
anthracyclines |
6 |
|
antiplatelet agents |
6 |
|
aorta, thoracic - pathology - radiography |
6 |
|
aortic diseases - epidemiology - radiography |
6 |
|
apolipoprotein a-i - metabolism |
6 |
|
arterial stiffiness |
6 |
|
arthritis, rheumatoid - complications |
6 |
|
arthritis, rheumatoid - complications - immunology - physiopathology |
6 |
|
aspirin - administration & dosage - adverse effects |
6 |
|
atherosclerosis - epidemiology - physiopathology - radiography |
6 |
|
atherosclerosis - epidemiology - radiography |
6 |
|
atrial fibrillation - complications |
6 |
|
atrioventricular block - complications - diagnosis - physiopathology |
6 |
|
biogenesis |
6 |
|
blood glucose - metabolism |
6 |
|
bone marrow |
6 |
|
bone marrow cells |
6 |
|
brachial artery - pathology |
6 |
|
brachial artery - physiopathology - ultrasonography |
6 |
|
brain ischemia - epidemiology - etiology |
6 |
|
c-reactive protein |
6 |
|
calcinosis - complications - epidemiology - radiography |
6 |
|
calcinosis - epidemiology - physiopathology - radiography |
6 |
|
calcium handling |
6 |
|
cancer |
6 |
|
cardiac pacing, artificial - methods |
6 |
|
cardiac progenitor cells |
6 |
|
cardiotonic agents - pharmacology |
6 |
|
cardiovascular continuum |
6 |
|
cardiovascular death |
6 |
|
cardiovascular diseases - blood - diet therapy - prevention & control |
6 |
|
cardiovascular diseases - epidemiology - physiopathology - radiography |
6 |
|
cardiovascular diseases - etiology - physiopathology |
6 |
|
cardiovascular event |
6 |
|
cardiovascular system - pathology - physiopathology - radiography |
6 |
|
carotid arteries - pathology - radiography |
6 |
|
carotid artery diseases - epidemiology - radiography |
6 |
|
carotid artery diseases - epidemiology - ultrasonography |
6 |
|
catheter ablation - methods |
6 |
|
cell density |
6 |
|
chads2 and cha2ds2-vasc scores |
6 |
|
computer tomography |
6 |
|
confounding factors (epidemiology) |
6 |
|
coronary artery calcium |
6 |
|
coronary artery disease - epidemiology - immunology - physiopathology |
6 |
|
coronary artery disease - epidemiology - radiography |
6 |
|
coronary vessels - pathology |
6 |
|
dabigatran |
6 |
|
deferiprone |
6 |
|
deficiency diseases - complications - physiopathology |
6 |
|
diabetes |
6 |
|
diabetes mellitus, type 2 - blood - drug therapy |
6 |
|
diet |
6 |
|
diet records |
6 |
|
drug interaction |
6 |
|
drug therapy, combination |
6 |
|
drug-eluting stents |
6 |
|
echocardiography, doppler |
6 |
|
elderly |
6 |
|
endothelial cells - cytology - physiology |
6 |
|
endothelium, vascular - cytology - physiology |
6 |
|
endothelium, vascular - immunology - pathology |
6 |
|
energy intake |
6 |
|
enzyme-linked immunosorbent assay |
6 |
|
epicardial patch |
6 |
|
estimated glomerular filtration rate |
6 |
|
exercise capacity |
6 |
|
friedreich ataxia |
6 |
|
friedreich's ataxia |
6 |
|
general diabetes |
6 |
|
glyburide - therapeutic use |
6 |
|
glycated hemoglobin a |
6 |
|
has-bled score |
6 |
|
high sensitive troponin level |
6 |
|
hip fractures |
6 |
|
homeostasis |
6 |
|
hyperglycemia - complications - epidemiology |
6 |
|
hypertension - complications - epidemiology |
6 |
|
hyperthyroidism |
6 |
|
hyperthyroidism - complications |
6 |
|
hypoglycemia |
6 |
|
hypoglycemic agents - therapeutic use |
6 |
|
idebenone |
6 |
|
immunohistochemistry |
6 |
|
induced pluripotent stem cell |
6 |
|
induced pluripotent stem cells - cytology |
6 |
|
intracranial hemorrhages - drug therapy - physiopathology - surgery |
6 |
|
ischemic cardiomyopathy |
6 |
|
lipocalin |
6 |
|
liver stiffness |
6 |
|
lupus erythematosus, systemic - complications - physiopathology |
6 |
|
mediterranean-style diet |
6 |
|
mesenchymal stem cells - immunology - pathology |
6 |
|
mice, inbred c57bl |
6 |
|
mitochondrial transfer |
6 |
|
mitral valve |
6 |
|
multidetector computed tomography |
6 |
|
myocytes, cardiac - cytology/drug effects - metabolism |
6 |
|
non-st elevated myocardial infarction |
6 |
|
nonvalvular atrial fibrillation |
6 |
|
non–vitamin k oral anticoagulant |
6 |
|
nutrition |
6 |
|
nutrition assessment |
6 |
|
pacemaker, artificial |
6 |
|
pathophysiological mechanism |
6 |
|
pericardium - pathology - physiopathology |
6 |
|
phytoestrogen |
6 |
|
phytoestrogens - administration & dosage |
6 |
|
platelet aggregation inhibitors - administration & dosage - adverse effects |
6 |
|
pluripotent stem cells - cytology |
6 |
|
postmenopause |
6 |
|
pr interval prolongation |
6 |
|
primary prevention |
6 |
|
proliferation |
6 |
|
proportional hazards models |
6 |
|
prosthesis implantation - methods |
6 |
|
psoriasis - epidemiology |
6 |
|
rage |
6 |
|
receptors, immunologic - blood - drug effects |
6 |
|
recurrent stroke |
6 |
|
renal dysfunction |
6 |
|
risk |
6 |
|
selenium - administration & dosage - deficiency |
6 |
|
selenium deficiency |
6 |
|
sglt2 inhibitors |
6 |
|
sleep apnea syndromes - complications - physiopathology |
6 |
|
soluble receptor for advanced glycation end-products |
6 |
|
st segment elevation myocardial infarction |
6 |
|
statin intolerance |
6 |
|
stroke/prevention |
6 |
|
thiazolidinedione |
6 |
|
thiazolidinediones - therapeutic use |
6 |
|
timi grading system |
6 |
|
tomography, spiral computed |
6 |
|
trace elements - deficiency |
6 |
|
type 2 |
6 |
|
vascular calcification |
6 |
|
vascular diseases - etiology - physiopathology |
6 |
|
vascular dysfunction |
6 |
|
ventricular dysfunction, left - physiopathology - surgery |
6 |
|
visit-to-visit blood pressure variability |
6 |
|
16s rdna gene |
5 |
|
3t3-l1 cells |
5 |
|
ace2 expression and distribution |
5 |
|
acute kidney injury |
5 |
|
adenosine triphosphate |
5 |
|
adenoviridae - genetics |
5 |
|
adipocytes - metabolism |
5 |
|
adiponectin - blood - genetics - metabolism |
5 |
|
adipose tissue - drug effects - metabolism |
5 |
|
administration, oral |
5 |
|
adriamycin nephropathy |
5 |
|
algorithms |
5 |
|
amiodarone - adverse effects - analogs and derivatives |
5 |
|
anti-arrhythmia agents - therapeutic use |
5 |
|
antibiotic agent |
5 |
|
antigens, cd34 - analysis |
5 |
|
aorta, thoracic - drug effects - metabolism - physiopathology |
5 |
|
arteries - pathology |
5 |
|
arteriosclerosis - etiology - pathology - ultrasonography |
5 |
|
arthritis, rheumatoid - complications - pathology - physiopathology |
5 |
|
asian continental ancestry group |
5 |
|
atrial fibrillation - pathology - therapy |
5 |
|
atrial fibrillation and stroke |
5 |
|
autophagy |
5 |
|
axial spondyloarthritis |
5 |
|
bacteria |
5 |
|
bacteria - classification - genetics - isolation & purification |
5 |
|
bacterial infections - microbiology |
5 |
|
bacteriological techniques |
5 |
|
bcd-ipsc disease model |
5 |
|
blood glucose - drug effects |
5 |
|
bone marrow transplantation - methods - physiology |
5 |
|
brachial artery - drug effects - physiology |
5 |
|
brugada syndrome |
5 |
|
c-reactive protein - metabolism |
5 |
|
calcinosis - epidemiology - etiology - pathology |
5 |
|
cardiac dysfunction |
5 |
|
cardiac function reserve |
5 |
|
cardiac pacing, artificial |
5 |
|
cardiovascular |
5 |
|
cardiovascular diseases - mortality |
5 |
|
carotid arteries - pathology |
5 |
|
carotid arteries - pathology - ultrasonography |
5 |
|
children |
5 |
|
china |
5 |
|
chronic disease |
5 |
|
clinical characteristics |
5 |
|
coagulation |
5 |
|
comorbidity |
5 |
|
computed tomography |
5 |
|
computer applications |
5 |
|
coronary angiography |
5 |
|
coronary calcification |
5 |
|
coronary intervention |
5 |
|
cyp2c9 |
5 |
|
cyp4v2 gene mutant psc control |
5 |
|
diabetes mellitus, type 2 - blood - drug therapy - metabolism |
5 |
|
diabetes mellitus, type 2 - pathology - physiopathology |
5 |
|
diabetic cardiomyopathy |
5 |
|
diabetic retinopathy |
5 |
|
diastolic function |
5 |
|
dietary fats - administration & dosage |
5 |
|
discovery |
5 |
|
disease severity |
5 |
|
dna, bacterial - chemistry - genetics |
5 |
|
dna, ribosomal - chemistry - genetics |
5 |
|
dronedarone |
5 |
|
effective regurgitant orifice area (eroa) |
5 |
|
electrical cardioversion |
5 |
|
electrical stimulation |
5 |
|
electrocardiography, ambulatory |
5 |
|
electronics |
5 |
|
electrophysiologic techniques, cardiac |
5 |
|
embryonic stem cell-derived mesenchymal stem cells |
5 |
|
embryonic stem cells - cytology - drug effects - metabolism |
5 |
|
embryonic stem cells - drug effects - enzymology - physiology |
5 |
|
endothelial cells - cytology |
5 |
|
endothelial cells - physiology |
5 |
|
endothelium, vascular - cytology - metabolism |
5 |
|
endothelium, vascular - drug effects |
5 |
|
endothelium, vascular - pathology - ultrastructure |
5 |
|
endothelium, vascular - physiology |
5 |
|
enos |
5 |
|
exercise |
5 |
|
exercise echocardiography |
5 |
|
exosome |
5 |
|
fatal outcome |
5 |
|
fibrinolytic agents - pharmacology - therapeutic use |
5 |
|
fibroblast growth factor 21 |
5 |
|
fibrosis |
5 |
|
fish oil |
5 |
|
flow-mediated dilatation |
5 |
|
flow-mediated dilation |
5 |
|
gene transfer techniques |
5 |
|
genes, rrna |
5 |
|
genetic analysis |
5 |
|
genetic vectors |
5 |
|
genome - genetics |
5 |
|
glycogen storage disease type iib |
5 |
|
guinea pigs |
5 |
|
heart valve diseases - epidemiology - etiology - pathology |
5 |
|
hematopoietic stem cells - cytology |
5 |
|
hong kong - epidemiology |
5 |
|
human |
5 |
|
hyperglycemia |
5 |
|
hypernatraemia |
5 |
|
hypoglycemic agents - pharmacology - therapeutic use |
5 |
|
identification |
5 |
|
infection |
5 |
|
integrated care |
5 |
|
intermittent hypoxia |
5 |
|
ion channels |
5 |
|
ischaemic myocardium |
5 |
|
ischaemic stroke |
5 |
|
isoflavones - administration and dosage - therapeutic use |
5 |
|
lamin a/c |
5 |
|
leadless pacemaker |
5 |
|
left ventricular longitudinal strain |
5 |
|
left-sided valve disease |
5 |
|
leukocytes, mononuclear - physiology |
5 |
|
lipocalins - genetics - physiology |
5 |
|
liver and renal dysfunction |
5 |
|
lmna |
5 |
|
logistic models |
5 |
|
lung - physiopathology |
5 |
|
lung development |
5 |
|
lung diseases - chemically induced |
5 |
|
lung progenitor cells |
5 |
|
lupus erythematosus, systemic - complications - pathology - physiopathology |
5 |
|
magnetic resonance angiography - methods |
5 |
|
mesenchymal stem cell |
5 |
|
metabolic syndrome |
5 |
|
metabolic syndrome x - complications - physiopathology |
5 |
|
methylprednisolone |
5 |
|
mexiletine |
5 |
|
mice, knockout |
5 |
|
microspheres |
5 |
|
microwaves - therapeutic use |
5 |
|
model for end-stage liver disease |
5 |
|
monomorphic ventricular tachycardia |
5 |
|
multivariate analysis |
5 |
|
mus |
5 |
|
myocardial ischemia - physiopathology |
5 |
|
myocardial revascularization - methods |
5 |
|
myocytes, cardiac - drug effects - enzymology - physiology |
5 |
|
neovascularization |
5 |
|
neovascularization, physiologic |
5 |
|
non-vitamin k antagonist oral anticoagulants |
5 |
|
obesity - blood - metabolism |
5 |
|
obesity - metabolism - physiopathology |
5 |
|
oncogene proteins - deficiency - genetics - physiology |
5 |
|
pacemakers |
5 |
|
paracrine communication |
5 |
|
patients’ ages |
5 |
|
periodontal disease |
5 |
|
periodontitis |
5 |
|
plasminogen activator inhibitor 1 - blood - genetics - metabolism |
5 |
|
poly-unsaturated fatty acid |
5 |
|
polymorphic ventricular tachycardia |
5 |
|
polysomnography |
5 |
|
ppar gamma - agonists - metabolism |
5 |
|
prevention |
5 |
|
pulmonary arterial hypertension |
5 |
|
quinidine |
5 |
|
randomized clinical trial |
5 |
|
randomized controlled trial |
5 |
|
rats |
5 |
|
recombinant proteins - metabolism |
5 |
|
regenerative medicine |
5 |
|
rheumatic valvular heart disease |
5 |
|
risk assessment |
5 |
|
rna, bacterial - genetics |
5 |
|
rna, ribosomal, 16s - genetics |
5 |
|
rpe |
5 |
|
sars-cov-2 virus |
5 |
|
sequence analysis, dna - standards |
5 |
|
sequencing |
5 |
|
serpin e2 |
5 |
|
serpins - blood - metabolism |
5 |
|
sex |
5 |
|
sodium |
5 |
|
soybean proteins - therapeutic use |
5 |
|
statins |
5 |
|
stem cell |
5 |
|
stress |
5 |
|
stroke - pathology |
5 |
|
sulfonylurea compounds - pharmacology - therapeutic use |
5 |
|
surgery |
5 |
|
systemic calcified atherosclerosis |
5 |
|
systemic sclerosis |
5 |
|
t-wave alternans |
5 |
|
testosterone |
5 |
|
thiazolidinediones - pharmacology - therapeutic use |
5 |
|
thrombotic dieases |
5 |
|
transduction, genetic |
5 |
|
tricuspid regurgitation (tr) |
5 |
|
tricuspid valve insufficiency |
5 |
|
triiodothyronine - pharmacology |
5 |
|
tunica intima - pathology |
5 |
|
tunica intima - ultrasonography |
5 |
|
tunica media - ultrasonography |
5 |
|
valvular calcification |
5 |
|
ventricular fibrillation |
5 |
|
ventricular function |
5 |
|
ventricular function, left |
5 |
|
vitamin d deficiency - pathology |
5 |
|
vulnerability |
5 |
|
x-linked vacuolar cardiomyopathy and myopathy |
5 |
|
2-hour ecg |
4 |
|
3-(4,5-dimethyl-thiazol-2-yl)-2,5-dephenyltetrazolium bromide |
4 |
|
abc pathway |
4 |
|
acacetin |
4 |
|
acei |
4 |
|
action potential |
4 |
|
action potentials - physiology |
4 |
|
adipocyte fatty acid-binding protein |
4 |
|
adipogenesis |
4 |
|
adiponectin |
4 |
|
adiponectin - blood |
4 |
|
afabp |
4 |
|
amino acid substitution |
4 |
|
amiodarone |
4 |
|
amiodarone - adverse effects |
4 |
|
amiodarone - therapeutic use |
4 |
|
amlodipine |
4 |
|
amlodipine - pharmacology - therapeutic use |
4 |
|
analysis of variance |
4 |
|
annonaceae |
4 |
|
anti-arrhythmia agents - adverse effects |
4 |
|
anti-bacterial agents - pharmacology |
4 |
|
antibiotic prophylaxis |
4 |
|
antibiotics |
4 |
|
anticholesteremic agents |
4 |
|
anticholesteremic agents - pharmacology - therapeutic use |
4 |
|
antigens, cd - metabolism |
4 |
|
antihypertensive agents - pharmacology - therapeutic use |
4 |
|
apocynin |
4 |
|
applications |
4 |
|
arb |
4 |
|
article |
4 |
|
asian |
4 |
|
atorvastatin |
4 |
|
atrial fibrillation - etiology - therapy |
4 |
|
atrial fibrillation - surgery |
4 |
|
atrial function - physiology |
4 |
|
atrial high rate |
4 |
|
atrioventricular block - physiopathology - therapy |
4 |
|
atrioventricular block - therapy |
4 |
|
automaticity |
4 |
|
bare-metal stents |
4 |
|
bioartificial pacemaker |
4 |
|
bioavailability |
4 |
|
biological clocks - physiology |
4 |
|
biological markers |
4 |
|
blood glucose |
4 |
|
blood pressure - drug effects |
4 |
|
blood pressure - drug effects - physiology |
4 |
|
bms309403 |
4 |
|
body temperature |
4 |
|
bone marrow cells - pathology |
4 |
|
bone marrow transplantation |
4 |
|
brachial artery - physiology - ultrasonography |
4 |
|
bradycardia |
4 |
|
brain natriuretic peptide |
4 |
|
bromodeoxyuridine |
4 |
|
cadmium - pharmacology |
4 |
|
cardiac pacing, artificial - adverse effects - methods |
4 |
|
cardioprotection |
4 |
|
cardiovascular diseases - blood - diagnosis - mortality |
4 |
|
cardiovascular diseases - epidemiology - metabolism |
4 |
|
cardiovascular diseases - ethnology - etiology |
4 |
|
cardiovascular diseases/prevention and control |
4 |
|
cardiovascular events |
4 |
|
cardiovascular outcomes |
4 |
|
carrier state - microbiology |
4 |
|
cell stretch |
4 |
|
cell therapy |
4 |
|
cerebellar hemorrhages |
4 |
|
challenges |
4 |
|
cholesterol - blood |
4 |
|
cholesterol, ldl |
4 |
|
chronic obstructive pulmonary disease |
4 |
|
cigarette smoke |
4 |
|
clinical trials |
4 |
|
cluster analysis |
4 |
|
co-enzyme q10 |
4 |
|
colony count, microbial |
4 |
|
community-acquired infections - epidemiology - microbiology |
4 |
|
congenital |
4 |
|
congestive heart failure |
4 |
|
corneal resurfacing |
4 |
|
corneal wound healing |
4 |
|
coronary artery disease - blood - complications - drug therapy |
4 |
|
coronary artery disease - diagnosis - epidemiology |
4 |
|
coronary artery disease - pathology |
4 |
|
coronary artery disease - physiopathology |
4 |
|
coronary artery disease - physiopathology - rehabilitation |
4 |
|
coronary artery disease - ultrasonography |
4 |
|
crispr/cas9 |
4 |
|
cross infection - microbiology |
4 |
|
cross-talk |
4 |
|
crt |
4 |
|
cryptogenic |
4 |
|
cyclic nucleotide-gated cation channels - drug effects |
4 |
|
cyclic nucleotide-gated cation channels - genetics |
4 |
|
dcm-associated mutations |
4 |
|
dementia |
4 |
|
diabetes mellitus - physiopathology |
4 |
|
diabetes mellitus, type 2 - blood - diagnosis - mortality |
4 |
|
diabetes mellitus, type 2 - blood - pathology |
4 |
|
diastole |
4 |
|
diet surveys |
4 |
|
diffusion magnetic resonance imaging |
4 |
|
diffusion magnetic resonance imaging - methods |
4 |
|
diffusion tensor imaging |
4 |
|
digoxin |
4 |
|
digoxin - therapeutic use |
4 |
|
dinoprost - analogs & derivatives - blood |
4 |
|
disease activity |
4 |
|
disease association |
4 |
|
dna fingerprinting |
4 |
|
dna, bacterial - genetics |
4 |
|
doppler echocardiography |
4 |
|
drug combinations |
4 |
|
dti |
4 |
|
dvr |
4 |
|
educational status |
4 |
|
efficacy |
4 |
|
electrophoresis, gel, pulsed-field |
4 |
|
end-stage renal disease |
4 |
|
endocarditis, bacterial - epidemiology - microbiology |
4 |
|
endocarditis, bacterial - microbiology |
4 |
|
endoplasmic reticulum stress |
4 |
|
endothelial regeneration |
4 |
|
endothelium |
4 |
|
endothelium cell |
4 |
|
endothelium, vascular - metabolism |
4 |
|
endothelium, vascular - metabolism - pathology |
4 |
|
enteric nervous system |
4 |
|
environmental microbiology |
4 |
|
epithelial-mesenchymal transition |
4 |
|
exercise - physiology |
4 |
|
exercise test |
4 |
|
extracellular matrix |
4 |
|
familial dilated cardiomyopathy |
4 |
|
flavones - metabolism - pharmacology |
4 |
|
fluoroquinolones |
4 |
|
fluoroscopy |
4 |
|
gene expression - drug effects |
4 |
|
gene transfer |
4 |
|
genetic engineering - methods |
4 |
|
genomics |
4 |
|
geriatric patients |
4 |
|
gi proteins |
4 |
|
glycoproteins - metabolism |
4 |
|
gram-positive bacterial infections |
4 |
|
hcn |
4 |
|
hcn channel |
4 |
|
health surveys |
4 |
|
heart atria - cytology - innervation |
4 |
|
heart conduction system - physiology |
4 |
|
heart diseases - complications - diagnosis |
4 |
|
heart failure - diagnosis - prevention & control |
4 |
|
heart failure - epidemiology - etiology - therapy |
4 |
|
heart failure - etiology |
4 |
|
heart rate - drug effects |
4 |
|
heart right ventricle |
4 |
|
heart ventricles |
4 |
|
heart ventricles - cytology |
4 |
|
heart ventricles - cytology - innervation |
4 |
|
heart ventricles - ultrasonography |
4 |
|
hek293 cells |
4 |
|
hemodynamics |
4 |
|
hemodynamics - physiology |
4 |
|
hepatocyte growth factor |
4 |
|
hepatokines |
4 |
|
heptanoic acids - pharmacology - therapeutic use |
4 |
|
hf |
4 |
|
high-sensitivity troponin i outcome |
4 |
|
hip fractures - surgery |
4 |
|
histamine |
4 |
|
hkv1.5 |
4 |
|
hrct |
4 |
|
human stem cells |
4 |
|
hypercholesterolemia - physiopathology |
4 |
|
hypertension - blood - complications - drug therapy |
4 |
|
hypertension - ultrasonography |
4 |
|
hypertension, pulmonary - diagnosis - prevention & control |
4 |
|
hypertension, pulmonary - drug therapy - etiology |
4 |
|
hypertension, pulmonary - physiopathology |
4 |
|
hyperthyroidism - complications - epidemiology - physiopathology |
4 |
|
hyperuricaemia |
4 |
|
i f |
4 |
|
i k1 |
4 |
|
immunomodulation |
4 |
|
implantable cardioverter-defibrillater |
4 |
|
implantable cardioverter-defibrillator |
4 |
|
implanted pacemaker |
4 |
|
in farct size |
4 |
|
induced pluripotent stem cell derived-mesenchymal stem cell |
4 |
|
induced pluripotent stem cells - cytology - metabolism |
4 |
|
infarct location |
4 |
|
infective endocarditis |
4 |
|
infusions, intravenous |
4 |
|
insertable cardiac monitor |
4 |
|
insulin resistance |
4 |
|
interleukins |
4 |
|
interstitial lung disease |
4 |
|
ion channel gating - physiology |
4 |
|
ipsc-induced hepatocytes |
4 |
|
ipscs-derived cardiomyocyte-based disease model |
4 |
|
ipscs-derived cerebral cortical neurons |
4 |
|
ischemia reperfusion injury |
4 |
|
isoflavones - administration & dosage |
4 |
|
kidney failure, chronic - physiopathology - therapy |
4 |
|
kir2.1 |
4 |
|
kv1.5 potassium channel - antagonists and inhibitors - chemistry - genetics |
4 |
|
lactococcus |
4 |
|
lamin a/c cardiomyopathy |
4 |
|
lamp2 deficiency |
4 |
|
left ventricular dysfunction |
4 |
|
left ventricular dyssynchrony |
4 |
|
lesion |
4 |
|
lipid metabolism - drug effects - physiology |
4 |
|
long-term outcome |
4 |
|
longitudinal cardiac change |
4 |
|
lung artery pressure |
4 |
|
lung vascular resistance |
4 |
|
lysosomal membrane permeabilization |
4 |
|
macrophages |
4 |
|
major clinical study |
4 |
|
manufacturers |
4 |
|
masld |
4 |
|
mesenchymal stromal cell |
4 |
|
metabolic reprogramming |
4 |
|
metabolic syndrome x - complications - ethnology |
4 |
|
methicillin resistance |
4 |
|
meticillin-resistant staphylococcus aureus |
4 |
|
microarray |
4 |
|
microwave |
4 |
|
mitochondrial defect |
4 |
|
mitochondrial function |
4 |
|
mitogen-activated protein kinase 1 - metabolism |
4 |
|
mitogen-activated protein kinase 3 - metabolism |
4 |
|
mitrephora monocarpa |
4 |
|
muscle, skeletal - pathology - physiology - surgery |
4 |
|
myoblasts, skeletal - pathology |
4 |
|
myocardial fiber |
4 |
|
myocardial infarction - pathology |
4 |
|
myocardial infarction - pathology - physiopathology - therapy |
4 |
|
myocardium - metabolism - pathology |
4 |
|
myocardium infarction |
4 |
|
myocytes, cardiac - cytology - drug effects - metabolism |
4 |
|
myocytes, cardiac - cytology - physiology |
4 |
|
n-propyl caffeamide |
4 |
|
nasal colonisation |
4 |
|
neural development |
4 |
|
new species |
4 |
|
nfκb |
4 |
|
nitric oxide |
4 |
|
nitroglycerin - metabolism |
4 |
|
nitroglycerin-mediated dilatation |
4 |
|
nonsense mutation |
4 |
|
nose - microbiology |
4 |
|
open channel blockade |
4 |
|
osteoporotic fractures - surgery |
4 |
|
ouabain |
4 |
|
ouabain - pharmacology |
4 |
|
oxidative stress-induced apoptosis |
4 |
|
oxygen consumption - physiology |
4 |
|
pacemaker channels |
4 |
|
patch clamp |
4 |
|
patient-specific-induced pluripotent stem cells |
4 |
|
peptides - metabolism |
4 |
|
pharmacokinetics |
4 |
|
physical activity level |
4 |
|
physical endurance - physiology |
4 |
|
placebos |
4 |
|
polyunsaturated fatty acids |
4 |
|
porcine coronary artery angioplasty |
4 |
|
post-stroke care |
4 |
|
postoperative complications/prevention & control |
4 |
|
potassium channel blockers - metabolism - pharmacology |
4 |
|
premature atrial complexes |
4 |
|
preoperative care - methods |
4 |
|
priority journal |
4 |
|
progenitor cells |
4 |
|
prospects |
4 |
|
psc-based model |
4 |
|
ptc124 |
4 |
|
pulmonary artery |
4 |
|
pulmonary artery - ultrasonography |
4 |
|
pulmonary artery systolic pressure |
4 |
|
pulse wave velocity |
4 |
|
pyrimidines - pharmacology |
4 |
|
pyrroles - pharmacology - therapeutic use |
4 |
|
radiofrequency |
4 |
|
rap1 |
4 |
|
rate-dependent blockade |
4 |
|
regeneration |
4 |
|
regional wall motion abnormality |
4 |
|
remodeling |
4 |
|
renin–angiotensin–aldosterone system |
4 |
|
reprogramming |
4 |
|
respiratory diseases |
4 |
|
retinal ganglion cell |
4 |
|
rheumatic diseases - complications - ethnology |
4 |
|
rheumatic heart disease - epidemiology |
4 |
|
ros |
4 |
|
septal pacing |
4 |
|
severity of illness index |
4 |
|
sex-specific effect |
4 |
|
sleep apnea, central - diagnosis - prevention & control |
4 |
|
smoking |
4 |
|
smoking - adverse effects |
4 |
|
soybean proteins - administration & dosage |
4 |
|
soybeans - chemistry |
4 |
|
staphylococcal infections - microbiology |
4 |
|
staphylococcus aureus |
4 |
|
staphylococcus aureus - classification - drug effects - isolation & purification |
4 |
|
stem cell factor |
4 |
|
stem cell model |
4 |
|
stem cell transplantation |
4 |
|
stem cells - metabolism |
4 |
|
stem cells - metabolism - pathology |
4 |
|
strain rate |
4 |
|
substance abuse, intravenous - epidemiology |
4 |
|
sudden arrhythmic death |
4 |
|
sudden cardiac death |
4 |
|
sudden death |
4 |
|
superoxide dismutase - blood |
4 |
|
surgical |
4 |
|
symptoms |
4 |
|
synergism |
4 |
|
systolic blood pressure |
4 |
|
tachycardia, ventricular - diagnosis - epidemiology |
4 |
|
technique |
4 |
|
thailand |
4 |
|
three-dimensional echocardiography |
4 |
|
thyrotoxicosis - chemically induced |
4 |
|
tonic blockade |
4 |
|
transgenic mice model |
4 |
|
translational read through |
4 |
|
tricuspid valve geometry |
4 |
|
triglycerides - blood |
4 |
|
troponin |
4 |
|
troponin i - blood |
4 |
|
trpv4 channel |
4 |
|
tunica intima - pathology - ultrasonography |
4 |
|
tunica media - pathology - ultrasonography |
4 |
|
ubiquinone - administration & dosage - analogs & derivatives - metabolism |
4 |
|
uric acid |
4 |
|
valves |
4 |
|
vascular resistance - physiology |
4 |
|
vascular smooth muscle cells |
4 |
|
ventricular dysfunction, left - diagnosis - epidemiology |
4 |
|
ventricular dysfunction, left - epidemiology - etiology - physiopathology - ultrasonography |
4 |
|
ventricular dysfunction, left - epidemiology - etiology - therapy |
4 |
|
ventricular dyssynchrony |
4 |
|
ventricular function, left - drug effects |
4 |
|
ventricular function, left - physiology |
4 |
|
ventricular function, right - physiology |
4 |
|
ventricular tachycardia, ventricular fibrillation |
4 |
|
warfarin |
4 |
|
β-lactams |
4 |
|
*food habits |
3 |
|
*life style |
3 |
|
*motor activity |
3 |
|
*vascular stiffness |
3 |
|
4-aminopyridine - pharmacology |
3 |
|
5-fluorouracil |
3 |
|
action potentials |
3 |
|
action potentials - drug effects |
3 |
|
acute disease |
3 |
|
acute myocardial infarction |
3 |
|
adenovirus |
3 |
|
adipocytes - cytology |
3 |
|
allergy |
3 |
|
amino acid sequence |
3 |
|
amygdalin |
3 |
|
aneuploidy |
3 |
|
angioplasty, balloon, coronary - adverse effects - instrumentation - mortality |
3 |
|
angioplasty, balloon, coronary - adverse effects - mortality |
3 |
|
angiotensin-converting enzyme inhibitors - therapeutic use |
3 |
|
anisotropy |
3 |
|
anti-arrhythmia agents - pharmacology |
3 |
|
anticoagulants - adverse effects |
3 |
|
anticoagulation |
3 |
|
antigens, cd - blood |
3 |
|
antigens, cd34 - blood |
3 |
|
antithyroid agents - therapeutic use |
3 |
|
aortic valve |
3 |
|
appendage pacing atrial dyssynchrony |
3 |
|
arrhythmia, sinus - diagnosis - epidemiology |
3 |
|
arrhythmias |
3 |
|
arrhythmias, cardiac - physiopathology - surgery |
3 |
|
arsenicals - administration & dosage - blood - therapeutic use |
3 |
|
arteries - physiopathology |
3 |
|
asia |
3 |
|
aspirin |
3 |
|
aspirin - therapeutic use |
3 |
|
atherosclerosis - etiology - physiopathology |
3 |
|
atrial appendage - physiopathology - ultrasonography |
3 |
|
atrial contraction velocity |
3 |
|
atrial fibrillation - complications - drug therapy - physiopathology |
3 |
|
atrial fibrillation - diagnosis - epidemiology |
3 |
|
atrial fibrillation - drug therapy - prevention & control |
3 |
|
atrial fibrillation - physiopathology - therapy - ultrasonography |
3 |
|
atrial flutter - surgery |
3 |
|
atrial function - drug effects |
3 |
|
atrial septum - physiopathology - ultrasonography |
3 |
|
atrial septum pacing |
3 |
|
atrial synchronous pacing |
3 |
|
atrial tachycardia |
3 |
|
atrioventricular block |
3 |
|
atrium |
3 |
|
atypical werner syndrome |
3 |
|
bacterial |
3 |
|
bioartificial organs |
3 |
|
biomarker |
3 |
|
biomarkers |
3 |
|
biventricular pacing |
3 |
|
blood cells - cytology - metabolism |
3 |
|
blood coagulation disorders - chemically induced - drug therapy |
3 |
|
blood component transfusion |
3 |
|
blood glucose/metabolism |
3 |
|
blood pressure - physiology |
3 |
|
blood vessel remodeling |
3 |
|
bone marrow cells - cytology - metabolism |
3 |
|
bone marrow transplantation - methods |
3 |
|
bone marrow-derived cells |
3 |
|
borderzone |
3 |
|
bundle-branch block - physiopathology - therapy |
3 |
|
c-reactive protein - analysis |
3 |
|
ca 2+-activated k + current voltage-gated k + current |
3 |
|
calcium channel blockers - therapeutic use |
3 |
|
calcium channels, l-type - metabolism |
3 |
|
calcium transients |
3 |
|
calreticulin |
3 |
|
capecitabine |
3 |
|
carbimazole - therapeutic use |
3 |
|
cardiac autonomic dysfunction |
3 |
|
cardiac death |
3 |
|
cardiac output |
3 |
|
cardiac output - physiology |
3 |
|
cardiac pacing, artificial - adverse effects - methods - trends |
3 |
|
cardiac rehabilitation |
3 |
|
cardiac resynchronization therapy |
3 |
|
cardiac-specific c-kit+ cells |
3 |
|
cardiomegaly - complications - radiography - radionuclide imaging |
3 |
|
cardiomyocyte |
3 |
|
cardiomyopathies |
3 |
|
cardiomyopathy, dilated - genetics |
3 |
|
cardiomyoplasty |
3 |
|
cardiorenal syndrome |
3 |
|
cardiospheres |
3 |
|
cardiovascular disease modeling |
3 |
|
cardiovascular diseases - etiology - mortality |
3 |
|
cardiovascular diseases/diagnosis/*etiology/physiopathology |
3 |
|
cardiovascular mortality |
3 |
|
caveolin 3 - metabolism |
3 |
|
cell communication - genetics |
3 |
|
cell count - methods |
3 |
|
cell differentiation - genetics |
3 |
|
charlson comorbidity index |
3 |
|
checklist |
3 |
|
china - epidemiology |
3 |
|
chromosome disorders - genetics - metabolism - physiopathology |
3 |
|
chronic periodontitis - blood |
3 |
|
chronic periodontitis - blood - therapy |
3 |
|
clinical care pathways |
3 |
|
clinical correlates |
3 |
|
clinical trial |
3 |
|
coagulants - administration & dosage |
3 |
|
colorectal carcinoma |
3 |
|
connective tissue disease |
3 |
|
connecxin 43 |
3 |
|
connexin |
3 |
|
connexin 43 - genetics - metabolism |
3 |
|
contrast media |
3 |
|
coronary artery disease - complications - mortality - therapy |
3 |
|
coronary artery disease - diagnosis - surgery |
3 |
|
coronary artery disease - drug therapy - physiopathology |
3 |
|
coronary artery disease - ethnology - mortality - radiography - therapy |
3 |
|
coronary artery disease/*blood/drug therapy/pathology/physiopathology |
3 |
|
coronary circulation |
3 |
|
cryosurgery - methods |
3 |
|
cyclic nucleotide-gated cation channels |
3 |
|
cyclic nucleotide-gated cation channels - chemistry - drug effects - genetics - metabolism |
3 |
|
cyclic nucleotide-gated cation channels - chemistry - metabolism |
3 |
|
cysteine - chemistry - genetics |
3 |
|
cysteine mutagenesis |
3 |
|
defibrillators, implantable |
3 |
|
defibrillators, implantable - statistics and numerical data |
3 |
|
delayed-action preparations |
3 |
|
denervation |
3 |
|
dextrans |
3 |
|
diabetes mellitus, type 2 - complications - mortality |
3 |
|
diagnostic errors |
3 |
|
dietary carbohydrates/*adverse effects |
3 |
|
differential in-gel electrophoresis |
3 |
|
diltiazem |
3 |
|
diltiazem - therapeutic use |
3 |
|
dithiothreitol - pharmacology |
3 |
|
dpp-4 inhibitors |
3 |
|
drug |
3 |
|
drug acquisition costs |
3 |
|
drug administration schedule |
3 |
|
drug screening |
3 |
|
drug toxicity |
3 |
|
drugs |
3 |
|
dyslipidemias - drug therapy - physiopathology |
3 |
|
echocardiography parameters |
3 |
|
electric stimulation |
3 |
|
electrocardiogram |
3 |
|
electrocardiography. |
3 |
|
electrodes, implanted - adverse effects |
3 |
|
embryo research |
3 |
|
embryonic stem cells - cytology - metabolism - physiology |
3 |
|
endocarditis |
3 |
|
endocarditis, bacterial - etiology - mortality - surgery |
3 |
|
endothelial cells - cytology - metabolism |
3 |
|
endothelial senescence |
3 |
|
endothelium, vascular/*metabolism/pathology/physiopathology |
3 |
|
epidemiological characteristics |
3 |
|
exercise test - methods |
3 |
|
exercise therapy |
3 |
|
f-18 fluorodeoxyglucose fdg |
3 |
|
feasibility studies |
3 |
|
ferumoxytol |
3 |
|
fiber architecture |
3 |
|
fibrinolytic agents - contraindications - therapeutic use |
3 |
|
flavones - pharmacology - therapeutic use |
3 |
|
fluorodeoxyglucose f18 - diagnostic use |
3 |
|
fluoropyrimidine |
3 |
|
fragmented qrs |
3 |
|
gap junctions - metabolism |
3 |
|
gene expression regulation, developmental |
3 |
|
genes |
3 |
|
gerotarget |
3 |
|
gingival hemorrhage - blood |
3 |
|
gingival recession - blood |
3 |
|
glycoproteins - blood |
3 |
|
gram-positive bacilli |
3 |
|
gram-positive bacterial infections - diagnosis |
3 |
|
heart - anatomy and histology |
3 |
|
heart - embryology |
3 |
|
heart conduction system - drug effects - physiopathology |
3 |
|
heart conduction system - physiopathology |
3 |
|
heart failure - etiology - physiopathology |
3 |
|
heart failure - etiology - physiopathology - therapy |
3 |
|
heart rate - physiology |
3 |
|
heart rate recovery |
3 |
|
heart valve diseases - surgery |
3 |
|
heart valve prosthesis |
3 |
|
heart valve prosthesis - adverse effects |
3 |
|
heart valve prosthesis implantation |
3 |
|
heart valve prosthesis implantation - adverse effects - instrumentation |
3 |
|
helix angle |
3 |
|
hemorrhagic stroke/transformation |
3 |
|
hepatorenal dysfunction |
3 |
|
high comorbidity burden |
3 |
|
hindlimb - blood supply |
3 |
|
hospital mortality |
3 |
|
human atrial myocytes |
3 |
|
human induced pluripotent stem cell |
3 |
|
human induced pluripotent stem cell (hipsc) |
3 |
|
human leukocyte antigen class ii |
3 |
|
human preadipocytes |
3 |
|
hutchinson gilford progeria |
3 |
|
hydroxymethylglutaryl-coa reductase inhibitors - adverse effects |
3 |
|
hydroxymethylglutaryl-coa reductase inhibitors - adverse effects - pharmacology - therapeutic use |
3 |
|
hydroxymethylglutaryl-coa reductase inhibitors - therapeutic use |
3 |
|
hyperkalaemia |
3 |
|
hyperpolarization-activated cyclic nucleotide |
3 |
|
hypertension, pulmonary - etiology - physiopathology - ultrasonography |
3 |
|
hyperthyroidism - complications - physiopathology - ultrasonography |
3 |
|
hypertrophic cardiomyopathy |
3 |
|
hypolipidemic agents - adverse effects - pharmacology - therapeutic use |
3 |
|
hypolipidemic agents - therapeutic use |
3 |
|
iloprost - administration and dosage |
3 |
|
image enhancement - methods |
3 |
|
image interpretation, computer-assisted - methods |
3 |
|
imaging, three-dimensional |
3 |
|
immune humanized mice |
3 |
|
implementation research |
3 |
|
indoles - adverse effects - pharmacology - therapeutic use |
3 |
|
induced pluripotent stem cells - cytology - physiology |
3 |
|
inner pore |
3 |
|
inter- or intraatrial synchronicity |
3 |
|
international normalized ratio |
3 |
|
intrinsic cardiac abnormality |
3 |
|
ion channel gating - drug effects - genetics |
3 |
|
ion channels - classification - genetics - metabolism |
3 |
|
ion channels - genetics |
3 |
|
iron - diagnostic use |
3 |
|
ischemia - surgery |
3 |
|
isosorbide dinitrate - administration & dosage - adverse effects - analogs & derivatives |
3 |
|
kaplan-meier estimate |
3 |
|
kidney tubules - cytology |
3 |
|
lactic acid/blood |
3 |
|
lamin type a - genetics |
3 |
|
laropiprant |
3 |
|
left atrial thrombus |
3 |
|
length of stay |
3 |
|
leukemia, promyelocytic, acute - diagnosis - drug therapy |
3 |
|
leukotriene b4-12-hydroxydehydrogenase |
3 |
|
lipids/blood |
3 |
|
lkb1 |
3 |
|
low-density lipoprotein cholesterol |
3 |
|
lung diseases - etiology - prevention and control |
3 |
|
lupus erythematosus, systemic - complications |
3 |
|
mace |
3 |
|
maces |
3 |
|
madit-ii trial |
3 |
|
magnetic resonance imaging |
3 |
|
magnetite nanoparticles |
3 |
|
malnutrition |
3 |
|
mecp2 mutation |
3 |
|
mediastinum - radiography - radionuclide imaging |
3 |
|
medicine, chinese traditional |
3 |
|
membrane potentials |
3 |
|
mesenchymal stem cells - cytology - metabolism |
3 |
|
mesenchymal stem cells - physiology |
3 |
|
metals |
3 |
|
microarray analysis |
3 |
|
mir-3059-5p |
3 |
|
mitochondria, heart - drug effects - metabolism |
3 |
|
mitochondria/*metabolism/pathology |
3 |
|
mitochondrial diseases - chemically induced - metabolism |
3 |
|
mitochondrial dysfunction |
3 |
|
models, animal |
3 |
|
mr myocardial perfusion registration |
3 |
|
muscle fibers, skeletal |
3 |
|
mycobacterium fortuitum |
3 |
|
mycobacterium infections, nontuberculous - diagnosis - etiology |
3 |
|
myocardial contraction |
3 |
|
myocardial fiber connectivity |
3 |
|
myocardial fiber orientation |
3 |
|
myocardial fiber pathway |
3 |
|
myocardial infarction - etiology |
3 |
|
myocardial infarction - mortality - physiopathology - rehabilitation |
3 |
|
myocardial infarction - mortality - prevention and control |
3 |
|
myocardial ischemia |
3 |
|
myocardial regeneration |
3 |
|
myocardium - pathology |
3 |
|
myocytes, cardiac |
3 |
|
myocytes, cardiac - cytology |
3 |
|
myocytes, cardiac - cytology - metabolism |
3 |
|
myocytes, cardiac - cytology - metabolism - physiology |
3 |
|
nedd4l |
3 |
|
nerve sprouting |
3 |
|
nerve tissue proteins - metabolism |
3 |
|
neuritogenesis |
3 |
|
neuroprotection |
3 |
|
nf-κb |
3 |
|
niacin |
3 |
|
niacin - adverse effects - pharmacology - therapeutic use |
3 |
|
nitrate |
3 |
|
nitric oxide synthase |
3 |
|
nnt |
3 |
|
non-vitamin k oral anticoagulants |
3 |
|
nonselective cation current |
3 |
|
normalized mutual information |
3 |
|
nrf-2 |
3 |
|
nucks |
3 |
|
nutritional status |
3 |
|
organogenesis - genetics |
3 |
|
osteogenesis |
3 |
|
outer pore |
3 |
|
oxides - administration & dosage - blood - therapeutic use |
3 |
|
oxides - diagnostic use |
3 |
|
pacemaker, artificial - adverse effects |
3 |
|
papillary muscles - anatomy and histology |
3 |
|
paroxysmal atria fibrillation |
3 |
|
paroxysmal atrial fibrillation |
3 |
|
patch-clamp techniques |
3 |
|
pathogeny |
3 |
|
patient selection |
3 |
|
peptides - blood |
3 |
|
peptides - pharmacology |
3 |
|
pericarditis |
3 |
|
pericarditis - complications - radiography - radionuclide imaging |
3 |
|
pericarditis - diagnosis - etiology |
3 |
|
periodontal attachment loss - blood |
3 |
|
periodontal pocket - blood |
3 |
|
perioperative care - methods |
3 |
|
peripheral vascular disease |
3 |
|
permanent pacemaker |
3 |
|
phagocytosis |
3 |
|
pharmacology |
3 |
|
pharmacy and pharmacology environmental studies |
3 |
|
plasma |
3 |
|
platelet aggregation inhibitors - contraindications - therapeutic use |
3 |
|
pluripotency |
3 |
|
pluripotent stem cells |
3 |
|
pluripotent stem cells - cytology - metabolism |
3 |
|
pluripotent stem cells - cytology - metabolism - physiology |
3 |
|
pluripotent stem cells - cytology - physiology |
3 |
|
pluripotent stem cells - cytology - transplantation |
3 |
|
positron emission tomography/computed tomography |
3 |
|
positron-emission tomography |
3 |
|
postoperative complications - prevention and control |
3 |
|
potassium - metabolism |
3 |
|
potassium channel blockers - pharmacology |
3 |
|
potassium channels |
3 |
|
potassium channels - chemistry - drug effects - genetics - metabolism |
3 |
|
potassium channels - chemistry - metabolism |
3 |
|
potassium channels - drug effects - physiology |
3 |
|
pr interval |
3 |
|
prediabetes |
3 |
|
predictive value of tests |
3 |
|
prevalence in south-eastern chinese |
3 |
|
primary aldosteronism |
3 |
|
progeria - genetics |
3 |
|
propylthiouracil - therapeutic use |
3 |
|
prostacyclin |
3 |
|
prostaglandin |
3 |
|
prosthesis-related infections |
3 |
|
prosthesis-related infections - etiology - mortality - surgery |
3 |
|
protein structure, quaternary - drug effects |
3 |
|
protein transport |
3 |
|
proteome - genetics |
3 |
|
proteomic |
3 |
|
proteomics |
3 |
|
psoriasis - complications - physiopathology |
3 |
|
pulmonary veins - surgery |
3 |
|
pulse wave analysis |
3 |
|
pyruvic acid/blood |
3 |
|
quality of life |
3 |
|
quality-of-life |
3 |
|
quantitative perfusion analysis |
3 |
|
rat mesenchymal stem cells |
3 |
|
refractory hypertension |
3 |
|
renin-angiotensin-aldosterone system |
3 |
|
reoperation |
3 |
|
repair |
3 |
|
resistant hypertension |
3 |
|
resting heart rate |
3 |
|
retroviral reprogramming |
3 |
|
rett syndrome |
3 |
|
rheumatology |
3 |
|
right ventricular apex |
3 |
|
right ventricular apical pacing |
3 |
|
right ventricular function |
3 |
|
risk-stratification |
3 |
|
rna, messenger - genetics - metabolism |
3 |
|
ryanodine receptor |
3 |
|
ryanodine receptor calcium release channel - metabolism |
3 |
|
secondary pulmonary hypertension |
3 |
|
sepsis - etiology - mortality |
3 |
|
serum uric acid |
3 |
|
sex differ |
3 |
|
shrna |
3 |
|
sick sinus syndrome - physiopathology - surgery |
3 |
|
sick sinus syndrome - physiopathology - ultrasonography |
3 |
|
simvastatin |
3 |
|
simvastatin - adverse effects - pharmacology - therapeutic use |
3 |
|
sinoatrial node |
3 |
|
sinoatrial node - physiology |
3 |
|
sinus node disease |
3 |
|
sirt1 |
3 |
|
skeletal myoblasts |
3 |
|
skin fibroblast |
3 |
|
soce channels |
3 |
|
somatic reprogramming |
3 |
|
species specificity |
3 |
|
staining and labeling |
3 |
|
stem cell characterization |
3 |
|
stem cells - cytology - metabolism |
3 |
|
stents |
3 |
|
strain |
3 |
|
stroke/systemic embolism |
3 |
|
sulfhydryl modification |
3 |
|
surrogate marker |
3 |
|
sympathetic innervation |
3 |
|
tachycardia, ventricular - etiology - prevention & control |
3 |
|
target organ damage |
3 |
|
tetraethylammonium - pharmacology |
3 |
|
tetrodotoxin-sensitive na + current |
3 |
|
tissue doppler imaging |
3 |
|
tissue engineering |
3 |
|
tnfsf15 |
3 |
|
tomography, emission-computed, single-photon |
3 |
|
tomography, emission-computed, single-photon - methods |
3 |
|
tomography, x-ray computed |
3 |
|
toxicology and environmental safety |
3 |
|
transcription, genetic |
3 |
|
transient outward k + current |
3 |
|
transient receptor potential channels |
3 |
|
transplantation |
3 |
|
treatment inertia |
3 |
|
trpc1 |
3 |
|
tunica media - pathology |
3 |
|
type 2 diabetic mellitus |
3 |
|
untreated hypertension |
3 |
|
urine - cytology |
3 |
|
variants |
3 |
|
vascular endothelial growth factor receptor-2 - blood |
3 |
|
vasodilator agents - administration & dosage - adverse effects |
3 |
|
vasodilator agents - administration and dosage |
3 |
|
vdd |
3 |
|
ventricular dysfunction, left - etiology - physiopathology |
3 |
|
ventricular dysfunction, left - mortality - prevention and control |
3 |
|
ventricular function, right |
3 |
|
ventricular rate control |
3 |
|
vitamin k - administration & dosage |
3 |
|
vvi |
3 |
|
waist-hip ratio |
3 |
|
warfarin - adverse effects |
3 |
|
wnt/β-catenin signaling pathway |
3 |
|
zd7288 |
3 |
|
4,4'-diisothiocyanostilbene-2,2'-disulfonic acid - pharmacology |
2 |
|
abcd1 |
2 |
|
accelerometry |
2 |
|
acs/nstemi |
2 |
|
action potentials - drug effects - physiology |
2 |
|
acute inferior myocardial infarction |
2 |
|
acute myocardial infarction/stemi |
2 |
|
adaptation, physiological |
2 |
|
adolescent |
2 |
|
aging, premature - metabolism |
2 |
|
allergic rhinitis |
2 |
|
aneurysm, dissecting - diagnosis - mortality - surgery |
2 |
|
angina |
2 |
|
angina pectoris - complications - therapy |
2 |
|
angina pectoris - etiology - physiopathology - radionuclide imaging - therapy |
2 |
|
angiocardiography |
2 |
|
angiotensin ii type 1 receptor blockers - therapeutic use |
2 |
|
anthracycline |
2 |
|
anti-hypertensive therapy |
2 |
|
antiarrhythmic agents |
2 |
|
antibodies, monoclonal - therapeutic use |
2 |
|
anticoagulant agent |
2 |
|
anticoagulants - administration & dosage |
2 |
|
anticoagulants - therapeutic use |
2 |
|
antigens, cd - analysis |
2 |
|
antihypertensive agents - administration & dosage |
2 |
|
antihypertensive agents - therapeutic use |
2 |
|
antihypertensive drugs |
2 |
|
aorta |
2 |
|
aorta stenosis |
2 |
|
aorta valve |
2 |
|
aortic aneurysm - diagnosis - mortality - surgery |
2 |
|
aortic diseases - diagnosis - mortality - surgery |
2 |
|
arrhythmias, cardiac - epidemiology - etiology - physiopathology - prevention & control |
2 |
|
arrhythmias, cardiac - epidemiology - physiopathology |
2 |
|
arrhythmias, cardiac - therapy |
2 |
|
arterial occlusive diseases - etiology - radiography |
2 |
|
arterio-arterial fistula - radiography - surgery |
2 |
|
artifacts |
2 |
|
asians |
2 |
|
aspirin - adverse effects - therapeutic use |
2 |
|
asthma |
2 |
|
atrial fibrillation - blood - drug therapy |
2 |
|
atrial fibrillation - complications - etiology - physiopathology |
2 |
|
atrial fibrillation - complications - surgery |
2 |
|
atrial fibrillation - complications - therapy |
2 |
|
atrial fibrillation - drug therapy - pathology |
2 |
|
atrial fibrillation - drug therapy - physiopathology |
2 |
|
atrial fibrillation - epidemiology - etiology |
2 |
|
atrial fibrillation - epidemiology - pathology - therapy |
2 |
|
atrial fibrillation - ethnology - genetics - pathology - physiopathology |
2 |
|
atrial fibrillation - physiopathology - therapy |
2 |
|
atrial fibrillation - prevention & control |
2 |
|
atrial fibrillation - prevention and control - therapy |
2 |
|
atrial fibrillation - therapy |
2 |
|
atrial function |
2 |
|
atrial function, left |
2 |
|
atrial function, right |
2 |
|
atrial myocytes |
2 |
|
atrioventricular node - physiopathology |
2 |
|
atrioventricular node - surgery |
2 |
|
australia |
2 |
|
autonomic nervous system - physiopathology |
2 |
|
autonomics |
2 |
|
barium compounds - metabolism |
2 |
|
baroreflex |
2 |
|
baroreflex failure |
2 |
|
bayes theorem |
2 |
|
bioengineering cardiac patch |
2 |
|
biological markers - metabolism |
2 |
|
biomarkers of extracellular matrix regulation and collagen turnover |
2 |
|
biopsy, needle |
2 |
|
biventricular pacing/defibrillation |
2 |
|
blood coagulation - drug effects |
2 |
|
blotting, western |
2 |
|
blotting, western - methods |
2 |
|
bone marrow cells - drug effects - metabolism |
2 |
|
bone marrow cells - physiology |
2 |
|
bone marrow transplantation - adverse effects |
2 |
|
bone marrow transplantation - physiology |
2 |
|
brachial artery - drug effects - physiopathology |
2 |
|
brachial artery - physiology |
2 |
|
bradycardia/therapy |
2 |
|
calcimycin - pharmacology |
2 |
|
calcium channel blockers - pharmacology |
2 |
|
calcium signaling - drug effects - genetics |
2 |
|
calcium signalling |
2 |
|
calibration |
2 |
|
carcinoma - complications - radiography |
2 |
|
carcinoma, hepatocellular - secondary - surgery - ultrasonography |
2 |
|
cardiac fibroblasts |
2 |
|
cardiac metastasis |
2 |
|
cardiac output, low - etiology - ultrasonography |
2 |
|
cardiac output, low - physiopathology - therapy |
2 |
|
cardiac pacing. |
2 |
|
cardiac regeneration and repair |
2 |
|
cardiac resynchronization |
2 |
|
cardiac resynchronization therapy - adverse effects |
2 |
|
cardiac resynchronization therapy devices |
2 |
|
cardiomyopathies - therapy |
2 |
|
cardiopulmonary exercise test |
2 |
|
cardiopulmonary function |
2 |
|
cardiopulmonary resuscitation |
2 |
|
cardiotonic agents - adverse effects - diagnostic use |
2 |
|
cardiotoxicity |
2 |
|
cardiovascular disease in women |
2 |
|
cardiovascular diseases - diagnosis - pathology - physiopathology - therapy |
2 |
|
cardiovascular diseases - drug therapy - physiopathology |
2 |
|
cardiovascular diseases - pathology - physiopathology - psychology |
2 |
|
cardiovascular regeneration |
2 |
|
cardiovascular risk |
2 |
|
carotid body tumor |
2 |
|
carotid body tumor - pathology - surgery |
2 |
|
cause of death |
2 |
|
cell cycle - drug effects |
2 |
|
cell cycle - drug effects - genetics |
2 |
|
cell cycle progression |
2 |
|
cell death |
2 |
|
cell membrane - metabolism |
2 |
|
cell proliferation - drug effects |
2 |
|
cell size |
2 |
|
cell volume |
2 |
|
cellular electrophysiology |
2 |
|
cha2ds2‐vasc score |
2 |
|
chemotaxis |
2 |
|
chemotherapy |
2 |
|
chest pain |
2 |
|
child |
2 |
|
chloride channels - antagonists & inhibitors - metabolism |
2 |
|
chloride channels - chemistry |
2 |
|
chloride channels - drug effects - genetics - metabolism |
2 |
|
chloride channels - drug effects - metabolism |
2 |
|
chloride channels - metabolism |
2 |
|
chlorides - metabolism |
2 |
|
chromanol 293b |
2 |
|
chromans - pharmacology |
2 |
|
chronic myocardial ischemia |
2 |
|
cigarette smoking |
2 |
|
cl- current |
2 |
|
cl-channel |
2 |
|
clinical |
2 |
|
clinical outcomes |
2 |
|
clinical translation |
2 |
|
clinical trials as topic |
2 |
|
clopidogrel |
2 |
|
clotrimazole - pharmacology |
2 |
|
cognitive impairment |
2 |
|
colectomy - adverse effects - methods |
2 |
|
colorectal cancer |
2 |
|
colorectal cancer surgery |
2 |
|
colorectal neoplasms - surgery |
2 |
|
combined modality therapy |
2 |
|
computational pressure-flow dynamics |
2 |
|
concomitant |
2 |
|
congenital heart disease |
2 |
|
congestive cardiomyopathy |
2 |
|
connexin 43 |
2 |
|
constriction, pathologic - etiology - ultrasonography |
2 |
|
continental population groups - genetics |
2 |
|
contrast media - diagnostic use |
2 |
|
coronary angiography - methods |
2 |
|
coronary artery disease (cad) |
2 |
|
coronary artery disease - complications - physiopathology |
2 |
|
coronary artery disease - complications - therapy |
2 |
|
coronary artery disease - epidemiology - prevention & control |
2 |
|
coronary artery disease - pathology - physiopathology - surgery |
2 |
|
coronary artery disease - pathology - therapy |
2 |
|
coronary artery disease - physiopathology - radiography |
2 |
|
coronary disease - epidemiology - prevention and control |
2 |
|
coronary disease - etiology - therapy |
2 |
|
coronary disease - radionuclide imaging - surgery |
2 |
|
coronary restenosis - prevention & control |
2 |
|
coronary vasospasm - chemically induced - complications - physiopathology |
2 |
|
coronary vessels - pathology - surgery |
2 |
|
coronary vessels - surgery |
2 |
|
cross-over studies |
2 |
|
cryoablation |
2 |
|
ct scan |
2 |
|
current |
2 |
|
cyclic adp ribose |
2 |
|
cyclic adp-ribose - pharmacology |
2 |
|
cyclin d1 - genetics - metabolism |
2 |
|
cyclin d1 - metabolism |
2 |
|
cyclin e - genetics - metabolism |
2 |
|
cyclin e - metabolism |
2 |
|
cytokines - blood |
2 |
|
cytokines - therapeutic use |
2 |
|
data and signal acquisition |
2 |
|
death, sudden, cardiac - etiology |
2 |
|
decellularized placenta |
2 |
|
defibrillators, implantable - adverse effects |
2 |
|
delayed rectifier k+ currents |
2 |
|
delayed rectifier potassium channels |
2 |
|
delayed rectifier potassium channels - antagonists & inhibitors |
2 |
|
demyelination |
2 |
|
depression |
2 |
|
depression - diagnosis |
2 |
|
device |
2 |
|
device removal |
2 |
|
diabetes mellitus, type 2 - complications |
2 |
|
diabetes mellitus, type 2 - complications - physiopathology |
2 |
|
diabetes mellitus, type 2 - drug therapy - physiopathology |
2 |
|
diabetic angiopathies - prevention & control |
2 |
|
differentiation |
2 |
|
diffusion |
2 |
|
diffusion tensor imaging - methods |
2 |
|
disease model |
2 |
|
disease modeling |
2 |
|
disease modelling |
2 |
|
docosahexaenoic acids - pharmacology |
2 |
|
drug discovery |
2 |
|
drug evaluation, preclinical |
2 |
|
drug tolerance - physiology |
2 |
|
drug-eluting stent |
2 |
|
dual coronary fistulas |
2 |
|
dual-site right atrial pacing |
2 |
|
dyslipidemia |
2 |
|
dyslipidemias - drug therapy - epidemiology |
2 |
|
echocardiography - instrumentation |
2 |
|
echocardiography - methods |
2 |
|
echocardiography, doppler - methods |
2 |
|
echocardiography, transesophageal |
2 |
|
egfr kinase |
2 |
|
eicosapentaenoic acid - pharmacology |
2 |
|
electric countershock - statistics and numerical data |
2 |
|
electrocardiography (ecg) |
2 |
|
electrodes |
2 |
|
electrodes, implanted |
2 |
|
electromagnetic fields |
2 |
|
electromagnetic fields - adverse effects |
2 |
|
electromagnetic interference |
2 |
|
electronic medical devices |
2 |
|
electrophysiology - methods |
2 |
|
enalapril - therapeutic use |
2 |
|
endocardium |
2 |
|
endocardium - anatomy & histology - radiography |
2 |
|
endocardium - pathology |
2 |
|
endothelial cell |
2 |
|
endothelial cells - metabolism |
2 |
|
endothelial cells - pathology - physiology |
2 |
|
endothelial progenitor cells (epcs) |
2 |
|
endothelium, vascular - cytology - pathology - physiopathology |
2 |
|
endothelium, vascular - physiopathology - ultrasonography |
2 |
|
endothelium-dependent vasodilation |
2 |
|
energy |
2 |
|
enzyme inhibitors - pharmacology |
2 |
|
epidermal growth factor receptor kinase |
2 |
|
epithelial cells |
2 |
|
equipment design |
2 |
|
equipment failure |
2 |
|
esophagus |
2 |
|
esophagus - anatomy & histology - radiography |
2 |
|
ether-a-go-go potassium channels - metabolism |
2 |
|
exercise tolerance |
2 |
|
exercise tolerance - physiology |
2 |
|
exosomes |
2 |
|
familial hypercholesterolemia |
2 |
|
fat pad |
2 |
|
fatty acids, omega-3 - therapeutic use |
2 |
|
feasibility |
2 |
|
femoral vein |
2 |
|
fibrillation |
2 |
|
fibrinolytic agents - administration and dosage - therapeutic use |
2 |
|
fibroblasts - cytology - metabolism |
2 |
|
fibroblasts - drug effects - metabolism |
2 |
|
fibroblasts - metabolism |
2 |
|
fibroblasts - pathology |
2 |
|
flow cytometry analysis |
2 |
|
fractional flow reserve |
2 |
|
fruit |
2 |
|
functional capacity |
2 |
|
gar |
2 |
|
gastrointestinal bleeding |
2 |
|
gastrointestinal hemorrhage - chemically induced - epidemiology - physiopathology |
2 |
|
gene expression regulation - drug effects |
2 |
|
gene therapy |
2 |
|
genetic engineering |
2 |
|
genetics |
2 |
|
genistein - pharmacology |
2 |
|
global longitudinal strain |
2 |
|
glucose-albumin ratio |
2 |
|
good manufacturing practice |
2 |
|
granulocyte macrophage colony-stimulating factor |
2 |
|
guillain barre syndrome |
2 |
|
health care outcomes |
2 |
|
health status disparities |
2 |
|
heart atria - anatomy & histology - radiography |
2 |
|
heart atria - cytology |
2 |
|
heart atria - cytology - pathology |
2 |
|
heart atria - metabolism |
2 |
|
heart atria - pathology |
2 |
|
heart atria - physiopathology |
2 |
|
heart atria - ultrasonography |
2 |
|
heart catheterization - methods |
2 |
|
heart conduction system - pathology - surgery |
2 |
|
heart failure - drug therapy - etiology |
2 |
|
heart failure - therapy |
2 |
|
heart failure with preserved ejection fraction |
2 |
|
heart left ventricle ejection fraction |
2 |
|
heart left ventricle failure |
2 |
|
heart neoplasms - secondary - ultrasonography |
2 |
|
heart ventricle arrhythmia |
2 |
|
heart ventricles - cytology - drug effects - metabolism |
2 |
|
heart ventricles - drug effects |
2 |
|
heart ventricles - pathology - surgery |
2 |
|
heart ventricles - physiopathology - radionuclide imaging |
2 |
|
hematoma |
2 |
|
hematoma - diagnosis - mortality - surgery |
2 |
|
hematopoietic stem cell mobilization |
2 |
|
hematopoietic stem cells (hscs) |
2 |
|
hematopoietic stem cells - immunology - metabolism - pathology |
2 |
|
heparin |
2 |
|
heparin - administration and dosage - therapeutic use |
2 |
|
heparin, low-molecular-weight - administration and dosage - therapeutic use |
2 |
|
hepatocellular carcinoma |
2 |
|
hepatocytes |
2 |
|
herb-drug interactions - physiology |
2 |
|
herbs |
2 |
|
hernia, hiatal - complications |
2 |
|
high density |
2 |
|
high-frequency low-tidal volume ventilation |
2 |
|
high-lipoprotein cholesterol |
2 |
|
human atrium |
2 |
|
human bone marrow |
2 |
|
human ether-à-go-go-related gene (herg) potassium channels |
2 |
|
human liver chimeric mice |
2 |
|
human pluripotent stem cell |
2 |
|
hypercholesterolemia - drug therapy - epidemiology |
2 |
|
hyperlipidemias - blood - drug therapy - epidemiology |
2 |
|
hypertension - complications |
2 |
|
hypertension - complications - drug therapy |
2 |
|
hypertension - drug therapy |
2 |
|
hypertension - drug therapy - etiology - physiopathology |
2 |
|
hypertension - drug therapy - physiopathology |
2 |
|
hypertension - physiopathology |
2 |
|
hyperthyroidism - chemically induced - complications |
2 |
|
hypertrophy, left ventricular - complications |
2 |
|
hypertrophy, left ventricular - diagnosis - prevention & control - ultrasonography |
2 |
|
hyperuricemia |
2 |
|
hypotension, orthostatic - physiopathology |
2 |
|
icd shock |
2 |
|
imaging, three-dimensional - methods |
2 |
|
immunoglobulin fab fragments - therapeutic use |
2 |
|
implantable cardioverter defibrillator (icd) |
2 |
|
implantable devices |
2 |
|
in vitro disease models |
2 |
|
incidental findings |
2 |
|
indoles - pharmacology |
2 |
|
induced pluripotent stem cells - metabolism - pathology |
2 |
|
intermediate conductance ca2+-activated k+ current |
2 |
|
intermediate-conductance calcium-activated potassium channels - antagonists & inhibitors - genetics - metabolism |
2 |
|
intermediate-conductance calcium-activated potassium channels - drug effects - genetics - metabolism |
2 |
|
intermediate-conductance calcium-activated potassium current |
2 |
|
international normalized ratio - methods |
2 |
|
intervals |
2 |
|
intraatrial reentrant tachycardia |
2 |
|
intramyocardial injection |
2 |
|
inward rectifier potassium current |
2 |
|
ion channel gating - drug effects |
2 |
|
ion channel modulation |
2 |
|
ion channels - antagonists & inhibitors - genetics - metabolism |
2 |
|
ion channels - metabolism |
2 |
|
ionophores - pharmacology |
2 |
|
ipsc-mscs |
2 |
|
ischemic preconditioning, myocardial |
2 |
|
isoproterenol - adverse effects - diagnostic use |
2 |
|
issue 159 |
2 |
|
k-channel |
2 |
|
kcnq1 potassium channel - genetics - metabolism |
2 |
|
ketanserin |
2 |
|
laser therapy - methods |
2 |
|
ldl receptor |
2 |
|
left atrial appendage closure |
2 |
|
left atrial function |
2 |
|
left atrial spontaneous echo contrast |
2 |
|
left bundle branch pacing |
2 |
|
left to right heart shunt |
2 |
|
left ventricular diastolic function |
2 |
|
left ventricular hypertrophy |
2 |
|
leigh syndrome |
2 |
|
lesion dimension |
2 |
|
leukocyte count |
2 |
|
leukocytosis - blood - diagnosis - epidemiology |
2 |
|
linear models |
2 |
|
lipid lowering medication |
2 |
|
lipid-modifying therapy |
2 |
|
lipids - blood |
2 |
|
liver neoplasms - pathology - surgery |
2 |
|
long qts |
2 |
|
low-density lipoprotein |
2 |
|
magnetic resonance angiography |
2 |
|
mechanism |
2 |
|
mechanisms |
2 |
|
mediastinal neoplasms - complications - radiography |
2 |
|
medical therapy |
2 |
|
medicine |
2 |
|
membrane potentials - drug effects - genetics |
2 |
|
mesenchymal stem cells (mscs) |
2 |
|
mesenchymal stem cells - cytology - pathology |
2 |
|
mesenchymal stem cells - drug effects - metabolism |
2 |
|
mesenchymal stem cells - immunology - metabolism - pathology |
2 |
|
monitoring, physiologic |
2 |
|
multi-variable bayesian |
2 |
|
muscle, smooth, vascular - cytology - pathology |
2 |
|
muscles - pathology |
2 |
|
myocardial dysfunction |
2 |
|
myocardial infarction - blood - epidemiology |
2 |
|
myocardial infarction - blood - pathology - prevention & control |
2 |
|
myocardial infarction - complications - drug therapy - physiopathology |
2 |
|
myocardial infarction - therapy |
2 |
|
myocardial ischemia - therapy |
2 |
|
myocardial perfusion imaging - methods |
2 |
|
myocardial repair |
2 |
|
myocardial reperfusion injury - blood - pathology - prevention & control |
2 |
|
myocardium |
2 |
|
myocardium - cytology |
2 |
|
myocytes, cardiac - drug effects - enzymology |
2 |
|
myocytes, cardiac - drug effects - metabolism |
2 |
|
myocytes, cardiac - drug effects - physiology |
2 |
|
nasal continuous positive airway pressure |
2 |
|
neovascularization, pathologic - therapy |
2 |
|
neurodegeneration |
2 |
|
neurology |
2 |
|
nifedipine - therapeutic use |
2 |
|
nitrate tolerance |
2 |
|
nitrate-mediated dilatation |
2 |
|
nitrates - therapeutic use |
2 |
|
nitrobenzoates - pharmacology |
2 |
|
nitroglycerin - pharmacology |
2 |
|
non-dipper hypertension |
2 |
|
nonpharmacologic therapy |
2 |
|
norepinephrine |
2 |
|
odds ratio |
2 |
|
omega-3 pufas |
2 |
|
open channel block |
2 |
|
orthostatic hypotension |
2 |
|
orthovanadate |
2 |
|
outcome and process assessment (health care) |
2 |
|
pacing algorithm |
2 |
|
pancreatitis |
2 |
|
paracrine effects |
2 |
|
pathogenesis |
2 |
|
patient-specific induced pluripotent stem cells |
2 |
|
pcsk9 antibodies |
2 |
|
peptic ulcer - complications |
2 |
|
pericardium - pathology |
2 |
|
periodontitis - complications |
2 |
|
phlebograph - methods |
2 |
|
phosphorylation |
2 |
|
phosphotyrosine - metabolism |
2 |
|
pig atrial myocytes |
2 |
|
pilot projects |
2 |
|
plant preparations - blood - therapeutic use |
2 |
|
plaque composition |
2 |
|
platelet |
2 |
|
platelet aggregation inhibitors - therapeutic use |
2 |
|
platelet glycoprotein gpiib-iiia complex - antagonists & inhibitors |
2 |
|
point mutation - genetics |
2 |
|
population-based cohort study |
2 |
|
positive-pressure respiration |
2 |
|
postoperative complications |
2 |
|
postoperative complications - diagnosis - drug therapy |
2 |
|
posture - physiology |
2 |
|
potassium channels - analysis - metabolism |
2 |
|
potassium channels - physiology |
2 |
|
potassium channels, inwardly rectifying - drug effects - genetics - metabolism |
2 |
|
potassium channels, tandem pore domain |
2 |
|
potassium channels, voltage-gated |
2 |
|
predictors |
2 |
|
proportionality |
2 |
|
protein tyrosine kinase |
2 |
|
protein tyrosine kinases |
2 |
|
protein tyrosine phosphatase |
2 |
|
protein tyrosine phosphatases |
2 |
|
protein tyrosine phosphorylation |
2 |
|
protein-tyrosine kinases - antagonists & inhibitors |
2 |
|
psychological tests |
2 |
|
pulmonary artery - radiography - surgery |
2 |
|
pulmonary edema - etiology - ultrasonography |
2 |
|
pulmonary embolism - complications - radiography |
2 |
|
pulmonary fibrosis |
2 |
|
race |
2 |
|
radionuclide ventriculography - methods |
2 |
|
radiopharmaceuticals - diagnostic use |
2 |
|
reaction time |
2 |
|
receptor, epidermal growth factor - antagonists & inhibitors - metabolism |
2 |
|
receptor, epidermal growth factor - antagonists and inhibitors - genetics - metabolism |
2 |
|
receptor, epidermal growth factor - metabolism |
2 |
|
recombinant cardiac hkcnq1/hkcne1 channel |
2 |
|
recombinant proteins - genetics - metabolism |
2 |
|
recovery of function |
2 |
|
recurrence - prevention & control |
2 |
|
recurrence - prevention and control |
2 |
|
red cell distribution width |
2 |
|
regional blood flow - physiology |
2 |
|
regression analysis |
2 |
|
renal artery - drug effects - physiopathology |
2 |
|
renal denervation |
2 |
|
renal function |
2 |
|
renin angiotensin system |
2 |
|
reverse transcriptase polymerase chain reaction |
2 |
|
rheumatic |
2 |
|
right heart failure |
2 |
|
right ventricular pacing site |
2 |
|
rna interference |
2 |
|
rna, small interfering - genetics - metabolism |
2 |
|
rna, small interfering - metabolism |
2 |
|
ryanodine - pharmacology |
2 |
|
scimitar syndrome - diagnosis - radiography |
2 |
|
scimitar syndrome - radiography |
2 |
|
scleroderma, systemic - epidemiology - physiopathology |
2 |
|
shal potassium channels |
2 |
|
shock - etiology - physiopathology |
2 |
|
short interference rna |
2 |
|
signal processing, computer-assisted |
2 |
|
single-blind method |
2 |
|
sleep apnea, obstructive - diagnosis - therapy |
2 |
|
snoring - etiology |
2 |
|
sodium channel blockers - pharmacology |
2 |
|
speckle tracking strain |
2 |
|
spontaneous echo contrast |
2 |
|
src family kinases |
2 |
|
src-family kinases - metabolism |
2 |
|
stem cells - pathology - physiology |
2 |
|
stress, psychological - diagnosis - psychology |
2 |
|
stroke - etiology - physiopathology - prevention & control |
2 |
|
stroke prevention |
2 |
|
stroke volume |
2 |
|
stroke volume - physiology |
2 |
|
structural remodeling |
2 |
|
subcutaneous implantable cardioverter-defibrillator |
2 |
|
sulfonamides - pharmacology |
2 |
|
supine position |
2 |
|
surgery, computer-assisted - methods |
2 |
|
survival |
2 |
|
survival analysis |
2 |
|
syncope - diagnosis |
2 |
|
t cell |
2 |
|
tachyarrhythmias |
2 |
|
tachycardia - diagnosis - physiopathology |
2 |
|
tachycardia, ventricular - complications - prevention & control |
2 |
|
tachycardia, ventricular - diagnosis - surgery |
2 |
|
tachycardia, ventricular - drug therapy - etiology |
2 |
|
target genome editing |
2 |
|
therapeutic products |
2 |
|
therapy |
2 |
|
therapy and pre-clinical research |
2 |
|
thiamine |
2 |
|
thiamine - administration & dosage - blood |
2 |
|
thromboembolic event |
2 |
|
ticlopidine - analogs & derivatives - therapeutic use |
2 |
|
tilt-table test - adverse effects - methods |
2 |
|
tissue therapy - trends |
2 |
|
tomography, x-ray computed - instrumentation - methods |
2 |
|
tomography, x-ray computed - methods |
2 |
|
transcutaneous electric nerve stimulation - adverse effects - methods |
2 |
|
transcutaneous electrical neuromuscle stimulation |
2 |
|
transducers |
2 |
|
transesophageal echocardiography |
2 |
|
transient outward k+ |
2 |
|
transmural heterogeneity |
2 |
|
transplantation, autologous |
2 |
|
tricuspid valve disease |
2 |
|
triglyceride |
2 |
|
trpm2 |
2 |
|
tyrphostins - pharmacology |
2 |
|
ultra-rapid delayed rectifier k+ |
2 |
|
uscom |
2 |
|
user-computer interface |
2 |
|
vagal syndromes |
2 |
|
vanadates - pharmacology |
2 |
|
vascular neoplasms - secondary - ultrasonography |
2 |
|
vascular reactivity |
2 |
|
vasodilation - drug effects - physiology |
2 |
|
vasodilator agents - pharmacology |
2 |
|
vasodilator agents - therapeutic use |
2 |
|
vegetables |
2 |
|
venous thrombosis - radiography |
2 |
|
ventricular dysfunction, left - epidemiology - physiopathology - ultrasonography |
2 |
|
ventricular dysfunction, left - physiopathology |
2 |
|
ventricular dysfunction, left - physiopathology - therapy |
2 |
|
ventricular dysfunction, right - physiopathology |
2 |
|
ventricular rate |
2 |
|
ventricular septum - physiology |
2 |
|
ventricular septum - physiopathology - radionuclide imaging |
2 |
|
ventricular tachycardia |
2 |
|
very long chain fatty acids |
2 |
|
vibrations |
2 |
|
virtual histology |
2 |
|
vitamin d deficiency |
2 |
|
volume sensitive cl- current |
2 |
|
volume-sensitive chloride current |
2 |
|
warfarin - administration & dosage |
2 |
|
warfarin - blood - therapeutic use |
2 |
|
white blood cell count |
2 |
|
workload |
2 |
|
x-linked adrenoleukodystrophy |
2 |
|
x-linked cardiomyopathy |
2 |
|
zotarolimus-eluting stent |
2 |
|
β-blocker |
2 |
|
abandoned leads |
1 |
|
abnormalities, multiple - diagnosis - pathology - surgery |
1 |
|
accidents, traffic |
1 |
|
acute kidney injury - etiology - metabolism |
1 |
|
adenocarcinoma - complications - secondary |
1 |
|
adenosine triphosphate - diagnostic use |
1 |
|
adrenergic beta-antagonists - therapeutic use |
1 |
|
adult stem cells |
1 |
|
adult stem cells - cytology - transplantation |
1 |
|
aha science advisory |
1 |
|
all-cause death |
1 |
|
alternative site pacing |
1 |
|
amlodipine - administration & dosage - adverse effects - therapeutic use |
1 |
|
aneurysm, false - radiography |
1 |
|
angiography |
1 |
|
angiography - methods |
1 |
|
angioplasty |
1 |
|
angioplasty, balloon, coronary |
1 |
|
angioplasty, balloon, coronary - adverse effects |
1 |
|
angioplasty, transluminal, percutaneous coronary |
1 |
|
angioplasty, transluminal, percutaneous coronary - adverse effects |
1 |
|
angiotensin ii |
1 |
|
angiotensin ii - pharmacology |
1 |
|
annexin a5 - metabolism - physiology |
1 |
|
anthranilic acids - pharmacology |
1 |
|
anti-arrhythmia agents |
1 |
|
anti-arrhythmia agents - administration & dosage |
1 |
|
anti-arrhythmia agents - administration & dosage - adverse effects - blood - therapeutic use |
1 |
|
anti-arrhythmia agents - administration and dosage - adverse effects - therapeutic use |
1 |
|
anti-arrhythmia agents - metabolism - pharmacology |
1 |
|
anti-arrhythmia agents - pharmacology - therapeutic use |
1 |
|
anticoagulant |
1 |
|
anticoagulants - administration and dosage |
1 |
|
anticoagulants - administration and dosage - adverse effects - therapeutic use |
1 |
|
antihypertensive agents - administration & dosage - adverse effects - therapeutic use |
1 |
|
antiplatelet |
1 |
|
antiplatelet agent |
1 |
|
antiplatelet drugs |
1 |
|
aorta - physiopathology |
1 |
|
arrhythmia - complications - therapy |
1 |
|
arrhythmias, cardiac - complications - prevention & control |
1 |
|
arrhythmias, cardiac - prevention & control |
1 |
|
arrhythmias/pacemakers/defibrillators |
1 |
|
arrythmias |
1 |
|
arterial tonometry |
1 |
|
arteriolar retinopathy |
1 |
|
arterioles - pathology |
1 |
|
artificial |
1 |
|
artificial intelligence |
1 |
|
aru |
1 |
|
asia pacific |
1 |
|
asia pacific heart rhythm society |
1 |
|
asia-pacific |
1 |
|
aspirin - administration & dosage |
1 |
|
aspirin - administration & dosage - therapeutic use |
1 |
|
aspirin - administration and dosage |
1 |
|
aspirin - pharmacology |
1 |
|
aspirin reaction unit |
1 |
|
asymptomatic |
1 |
|
atrial appendage |
1 |
|
atrial defibrillation |
1 |
|
atrial defibrillator |
1 |
|
atrial electrophysiology |
1 |
|
atrial febrillation |
1 |
|
atrial fibrillation - complications - diagnosis |
1 |
|
atrial fibrillation - complications - diagnosis - drug therapy - therapy |
1 |
|
atrial fibrillation - complications - diagnosis - surgery - therapy |
1 |
|
atrial fibrillation - complications - drug therapy - therapy |
1 |
|
atrial fibrillation - complications - epidemiology - therapy |
1 |
|
atrial fibrillation - complications - physiopathology |
1 |
|
atrial fibrillation - complications - physiopathology - prevention & control - therapy |
1 |
|
atrial fibrillation - complications - physiopathology - surgery |
1 |
|
atrial fibrillation - diagnosis - epidemiology - surgery |
1 |
|
atrial fibrillation - diagnosis - etiology - physiopathology |
1 |
|
atrial fibrillation - diagnosis - physiopathology - therapy |
1 |
|
atrial fibrillation - diagnosis - therapy |
1 |
|
atrial fibrillation - drug therapy - mortality |
1 |
|
atrial fibrillation - epidemiology - etiology - physiopathology - therapy |
1 |
|
atrial fibrillation - epidemiology - physiopathology - therapy |
1 |
|
atrial fibrillation - etiology |
1 |
|
atrial fibrillation - etiology - prevention & control - therapy |
1 |
|
atrial fibrillation - mortality - physiopathology - therapy - ultrasonography |
1 |
|
atrial fibrillation - mortality - prevention & control |
1 |
|
atrial fibrillation - pathology |
1 |
|
atrial fibrillation - physiopathology |
1 |
|
atrial fibrillation - physiopathology - prevention & control |
1 |
|
atrial fibrillation - physiopathology - prevention & control - ultrasonography |
1 |
|
atrial fibrillation - physiopathology - radiography - surgery |
1 |
|
atrial fibrillation - physiopathology - surgery |
1 |
|
atrial fibrillation - radiography - therapy |
1 |
|
atrial fibrillation burden |
1 |
|
atrial fibrillation detection |
1 |
|
atrial flutter |
1 |
|
atrial flutter - prevention & control |
1 |
|
atrial high rate episode |
1 |
|
atrial overdrive algorithm |
1 |
|
atrial overdrive pacing |
1 |
|
atrial pacing |
1 |
|
atrial premature complexes - complications - physiopathology |
1 |
|
atrial refractory period |
1 |
|
atrial tachyarrhythmia |
1 |
|
atrial vulnerable period |
1 |
|
atrioventricular block - complications - mortality - radiography |
1 |
|
atrioventricular interval |
1 |
|
atrioventricular nodal reentrant tachycardia |
1 |
|
atrioventricular node - physiopathology - surgery |
1 |
|
augmentation index |
1 |
|
automatic capture verification |
1 |
|
automatic mode |
1 |
|
automatic mode switching |
1 |
|
autonomic nerve block |
1 |
|
beta blockers |
1 |
|
beta-thromboglobulin - analysis |
1 |
|
biatrial shock |
1 |
|
biogeochemical cycle |
1 |
|
biventricular |
1 |
|
bleeding risk |
1 |
|
body surface potential mapping |
1 |
|
body surface potential mapping - instrumentation - methods |
1 |
|
body surface potential mapping - methods |
1 |
|
body weight |
1 |
|
bone marrow mononuclear cells |
1 |
|
brachial artery |
1 |
|
bradycardia - complications - therapy |
1 |
|
bradycardia - therapy |
1 |
|
bundle of his - physiopathology |
1 |
|
bundle-branch block - complications - diagnosis - physiopathology - therapy |
1 |
|
calcium - blood |
1 |
|
calcium channel blockers - poisoning |
1 |
|
calcium chloride - administration & dosage |
1 |
|
calcium chloride infusion |
1 |
|
captopril - therapeutic use |
1 |
|
cardiac electrophysiology |
1 |
|
cardiac pacing |
1 |
|
cardiac pacing, artificial - adverse effects |
1 |
|
cardiac pacing, artificial - economics - methods |
1 |
|
cardiac pacing, artificial - economics - utilization |
1 |
|
cardiac pacing, artificial - methods - mortality |
1 |
|
cardiac pacing, artificial - methods - standards |
1 |
|
cardiac pacing, artificial - mortality - statistics & numerical data |
1 |
|
cardiac regeneration |
1 |
|
cardiac remodeling |
1 |
|
cardiac resynchronization therapy - methods |
1 |
|
cardiac surgical procedures |
1 |
|
cardiac surgical procedures - instrumentation |
1 |
|
cardiac volume |
1 |
|
cardiography, impedance |
1 |
|
cardiology - methods |
1 |
|
cardiology general |
1 |
|
cardiomyopathy, dilated - complications - diagnosis - physiopathology - therapy |
1 |
|
cardiomyopathy, hypertrophic - complications - diagnosis - mortality - surgery |
1 |
|
cardiomyopathy, hypertrophic - complications - radiography |
1 |
|
cardiotonic agents - metabolism - pharmacology |
1 |
|
cardiovascular agents - administration and dosage |
1 |
|
cardiovascular diseases - ethnology - etiology - prevention & control |
1 |
|
cardiovascular diseases - pathology - physiopathology |
1 |
|
cardiovascular diseases - physiopathology - therapy |
1 |
|
cardiovascular diseases - therapy |
1 |
|
cardiovascular event reduction |
1 |
|
cardiovascular outcome |
1 |
|
cardioversion |
1 |
|
catheter ablation - adverse effects |
1 |
|
catheter ablation - economics - utilization |
1 |
|
catheter ablation - instrumentation - methods |
1 |
|
catheter ablation - methods - statistics & numerical data |
1 |
|
catheterization - methods |
1 |
|
catheterization, central venous |
1 |
|
catheterization, peripheral |
1 |
|
cattle |
1 |
|
cell culture |
1 |
|
cell culture techniques |
1 |
|
cell death - drug effects |
1 |
|
cell injury |
1 |
|
cell lineage |
1 |
|
cell movement |
1 |
|
cell proliferation |
1 |
|
cephalic vein cutdown |
1 |
|
cerebrovascular disorders |
1 |
|
chart review |
1 |
|
chi-square distribution |
1 |
|
cholesterol, ldl - blood |
1 |
|
chronic coronary syndrome |
1 |
|
chronotropic incompetence |
1 |
|
ck-mb |
1 |
|
clinical registries |
1 |
|
cognitive |
1 |
|
collagen - metabolism |
1 |
|
colony forming units |
1 |
|
colony-stimulating factors - therapeutic use |
1 |
|
complex fractionated atrial electrogram |
1 |
|
complex fractionated electrograms |
1 |
|
conditioned medium |
1 |
|
conduction delay |
1 |
|
confidence intervals |
1 |
|
conscious sedation |
1 |
|
consistent atrial pacing |
1 |
|
constriction, pathologic |
1 |
|
constriction, pathologic - prevention & control |
1 |
|
contrast media - administration & dosage |
1 |
|
copd |
1 |
|
coronary artery disease - drug therapy - mortality |
1 |
|
coronary artery disease - pathology - physiopathology |
1 |
|
coronary artery disease - therapy |
1 |
|
coronary circulation - drug effects |
1 |
|
coronary disease |
1 |
|
coronary disease - blood - drug therapy |
1 |
|
coronary mircoembolization |
1 |
|
coronary occlusion - diagnosis - etiology - prevention and control |
1 |
|
coronary sinus |
1 |
|
coronary vessels |
1 |
|
coronary vessels - pathology - physiopathology |
1 |
|
cost-benefit analysis |
1 |
|
craniocerebral trauma - complications - metabolism |
1 |
|
creatine kinase-myocardial band |
1 |
|
creatinine - blood |
1 |
|
cryoablation efficacy |
1 |
|
cryosurgery - adverse effects |
1 |
|
ddd pacing |
1 |
|
death, sudden, cardiac - epidemiology - etiology - prevention & control |
1 |
|
death, sudden, cardiac - prevention & control |
1 |
|
defibrillation |
1 |
|
defibrillation threshold |
1 |
|
defibrillator |
1 |
|
defibrillators, implantable - adverse effects - classification |
1 |
|
defibrillators, implantable - contraindications - standards |
1 |
|
defibrillators, implantable - economics - utilization |
1 |
|
defibrillators, imptantable |
1 |
|
defribillators |
1 |
|
developmental biology |
1 |
|
diabetes insipidus - etiology - metabolism |
1 |
|
diagnosis |
1 |
|
diagnosis, computer-assisted - methods |
1 |
|
diagnosis, differential |
1 |
|
diagnostic cytology |
1 |
|
diaphragm |
1 |
|
diltiazem - administration & dosage |
1 |
|
dipyridamole - diagnostic use |
1 |
|
direct oral anticoagulant |
1 |
|
disease progression |
1 |
|
distal protection device |
1 |
|
dna methylation |
1 |
|
dose |
1 |
|
drug resistance |
1 |
|
dual antiplatelet therapy |
1 |
|
dual chamber pacemaker |
1 |
|
dual chamber pacemakers |
1 |
|
dyslipidemias - blood - complications - drug therapy - ethnology |
1 |
|
east asia |
1 |
|
ebstein anomaly - diagnosis - physiopathology - surgery |
1 |
|
echocardiography, doppler, pulsed |
1 |
|
edoxaban |
1 |
|
ejection fraction |
1 |
|
elasticity imaging techniques |
1 |
|
electric conductivity |
1 |
|
electric countershock - adverse effects |
1 |
|
electric countershock - adverse effects - methods |
1 |
|
electric countershock - instrumentation |
1 |
|
electric countershock - instrumentation - methods |
1 |
|
electric countershock - methods |
1 |
|
electric impedance |
1 |
|
electric stimulation - instrumentation - methods |
1 |
|
electric stimulation - methods |
1 |
|
electricity |
1 |
|
electrocardiography - methods |
1 |
|
electrocardiography, ambulatory - methods |
1 |
|
electroencephalography |
1 |
|
electromagnetic phenomena |
1 |
|
electromechanical properties |
1 |
|
electrophysiologic techniques, cardiac - instrumentation |
1 |
|
electroshock |
1 |
|
embolism - epidemiology |
1 |
|
embolism - pathology - physiopathology |
1 |
|
endocardial mapping |
1 |
|
endocarditis - etiology |
1 |
|
endocardium - physiopathology |
1 |
|
endothelium, vascular - pathology - physiopathology |
1 |
|
energy metabolism |
1 |
|
entanglement |
1 |
|
equipment safety |
1 |
|
esophageal diseases - etiology - pathology |
1 |
|
esophageal fistula |
1 |
|
esophageal fistula - etiology |
1 |
|
estrogens - physiology |
1 |
|
ethnic differences |
1 |
|
europe |
1 |
|
european heart rhythm association |
1 |
|
evaluation studies as topic |
1 |
|
evidence-based medicine |
1 |
|
evoked response sensing |
1 |
|
evolocumab |
1 |
|
exercise test - adverse effects |
1 |
|
exit block |
1 |
|
factor xa - antagonists and inhibitors - metabolism |
1 |
|
factor xa inhibitor |
1 |
|
feedback |
1 |
|
femoral artery - radiography |
1 |
|
fibrinolytic agents - therapeutic use |
1 |
|
floating atrial electrode |
1 |
|
gated blood-pool imaging |
1 |
|
gender |
1 |
|
genomic testing |
1 |
|
global health |
1 |
|
h3k9 methylation |
1 |
|
headache - etiology - prevention & control |
1 |
|
heart - physiopathology |
1 |
|
heart - radionuclide imaging |
1 |
|
heart aneurysm - complications - radiography |
1 |
|
heart arrest |
1 |
|
heart assist device |
1 |
|
heart atria |
1 |
|
heart atria - drug effects - physiopathology |
1 |
|
heart atria - injuries |
1 |
|
heart atria - physiopathology - surgery |
1 |
|
heart atria - radiography - surgery |
1 |
|
heart block - blood - physiopathology - therapy |
1 |
|
heart block - pathology - physiopathology - radionuclide imaging - therapy |
1 |
|
heart block - physiopathology - radionuclide imaging - therapy |
1 |
|
heart block - physiopathology - therapy |
1 |
|
heart block - physiopathology - therapy - ultrasonography |
1 |
|
heart block - therapy |
1 |
|
heart catheterization - instrumentation |
1 |
|
heart conduction system |
1 |
|
heart conduction system - physiopathology - surgery |
1 |
|
heart conduction system - surgery |
1 |
|
heart diseases - complications |
1 |
|
heart failure - complications - drug therapy - physiopathology |
1 |
|
heart failure - complications - physiopathology |
1 |
|
heart failure - complications - prevention & control |
1 |
|
heart failure - complications - surgery |
1 |
|
heart failure - diagnosis - physiopathology - prevention & control |
1 |
|
heart failure - etiology - prevention & control |
1 |
|
heart failure - etiology - prevention & control - therapy |
1 |
|
heart failure - mortality - prevention & control |
1 |
|
heart failure - physiopathology - therapy |
1 |
|
heart injuries - etiology |
1 |
|
heart rhythm society |
1 |
|
heart septum - physiopathology - surgery |
1 |
|
heart septum - surgery |
1 |
|
heart transplantation |
1 |
|
heart ventricles - physiopathology |
1 |
|
heart ventricles - physiopathology - surgery |
1 |
|
heart-assist device |
1 |
|
hematologic disorders |
1 |
|
hematoma - etiology |
1 |
|
hemodynamics - drug effects |
1 |
|
hemoglobins - metabolism |
1 |
|
hemorrhage - epidemiology |
1 |
|
hemorrhage - etiology - prevention & control |
1 |
|
heptanoic acids - administration & dosage - adverse effects - therapeutic use |
1 |
|
heterochromatin |
1 |
|
his bundle pacing |
1 |
|
homocysteine |
1 |
|
homocysteine - blood |
1 |
|
hospitals |
1 |
|
hydroxymethylglutaryl-coa reductase inhibitors - administration & dosage - adverse effects - therapeutic use |
1 |
|
hyperhomocysteinemia - complications - epidemiology |
1 |
|
hypertension - chemically induced - physiopathology |
1 |
|
hypertension - complications - drug therapy - ethnology - physiopathology |
1 |
|
hypertension - diagnosis - physiopathology |
1 |
|
hypertension - epidemiology |
1 |
|
hypertrophy, left ventricular - complications - diagnosis - mortality - surgery |
1 |
|
hypokalemia - etiology - metabolism |
1 |
|
hypotension - chemically induced - drug therapy |
1 |
|
hypoxia-preconditioning |
1 |
|
icd |
1 |
|
image processing, computer-assisted - methods |
1 |
|
impedance cardiography |
1 |
|
implantable atrial defibrillator |
1 |
|
implantable cardioverter |
1 |
|
implantable cardioverter defibrillator |
1 |
|
in-hospital mortality |
1 |
|
individualized medicine |
1 |
|
induced pluripotent stem cells - metabolism - pathology - transplantation |
1 |
|
inferior wall myocardial infarction |
1 |
|
inferior wall myocardial infarction - complications - mortality - radiography |
1 |
|
inferior wall myocardial infarction - diagnosis - therapy |
1 |
|
inflammation - prevention and control |
1 |
|
inflammatory arthritis |
1 |
|
injections, intravenous |
1 |
|
interleukin-6 - metabolism |
1 |
|
interleukin-8 - metabolism |
1 |
|
internal cardioversion |
1 |
|
internationality |
1 |
|
intima-media thickness |
1 |
|
ion channels - antagonists & inhibitors |
1 |
|
ischemic attack, transient - diagnosis - etiology |
1 |
|
jugular veins - radiography - surgery |
1 |
|
kerala |
1 |
|
latin american heart rhythm society |
1 |
|
ldl-c reduction |
1 |
|
lead capping |
1 |
|
lead extraction |
1 |
|
lead implantation |
1 |
|
left bundle branch area pacing |
1 |
|
left ventricle |
1 |
|
left ventricular ejection fraction |
1 |
|
left ventricular pacing |
1 |
|
life tables |
1 |
|
lincrna-p21 |
1 |
|
linear ablation |
1 |
|
lipoprotein, ldl |
1 |
|
long noncoding rnas |
1 |
|
low body weight |
1 |
|
low energy cardioversion |
1 |
|
lung neoplasms - complications - pathology |
1 |
|
lymphatic metastasis |
1 |
|
lysosomal glycogen storage disease |
1 |
|
machine learning |
1 |
|
macroplastics |
1 |
|
magnetic catheter |
1 |
|
magnetics - instrumentation |
1 |
|
major bleedings |
1 |
|
management |
1 |
|
mapping |
1 |
|
mast cel |
1 |
|
mast cells - drug effects - physiology |
1 |
|
mechanoelectrical feedback |
1 |
|
membrane potentials - drug effects |
1 |
|
menopause - physiology |
1 |
|
metabolite profiling |
1 |
|
metabolomics |
1 |
|
methylmercury |
1 |
|
microplastics |
1 |
|
microscopy, electron, transmission |
1 |
|
mitral valve insufficiency - blood - complications - ultrasonography |
1 |
|
mitral valve insufficiency - complications - therapy |
1 |
|
mitral valve prolapse - blood - complications - ultrasonography |
1 |
|
mode switching |
1 |
|
molecular diagnostics |
1 |
|
monocytes |
1 |
|
ms |
1 |
|
muscle, skeletal - physiopathology |
1 |
|
muscular diseases - etiology |
1 |
|
myocardial contraction - physiology |
1 |
|
myocardial infarction - blood |
1 |
|
myocardial infarction - complications - therapy |
1 |
|
myocardial infarction - drug therapy - mortality |
1 |
|
myocardial infarction - epidemiology |
1 |
|
myocardial reperfusion injury - drug therapy |
1 |
|
myocardial revascularization |
1 |
|
myocardial stunning - drug therapy |
1 |
|
myocardium - metabolism - pathology - ultrastructure |
1 |
|
myocytes, cardiac - cytology - transplantation |
1 |
|
myocytes, cardiac - metabolism - pathology |
1 |
|
myocytes, cardiac - physiology |
1 |
|
myopotential noise |
1 |
|
necrosis |
1 |
|
netherlands |
1 |
|
nifedipine - poisoning |
1 |
|
nifedipine overdose |
1 |
|
no-reflow |
1 |
|
nomogram |
1 |
|
non-steroidal anti-inflammatory drugs |
1 |
|
non-valvular atrial fibrillation |
1 |
|
nsaid |
1 |
|
observational research |
1 |
|
ohio - epidemiology |
1 |
|
ophthalmoscopy |
1 |
|
optical coherence tomography |
1 |
|
or |
1 |
|
oral anticoagulation |
1 |
|
overdose |
1 |
|
oversensing |
1 |
|
p wave polarity |
1 |
|
p2y12 receptor antagonist |
1 |
|
p53 |
1 |
|
pacemaker atrioventricular delay |
1 |
|
pacemaker lead |
1 |
|
pacemaker programming |
1 |
|
pacemaker, artificial - economics |
1 |
|
paroxysmal supraventricular tachycardia |
1 |
|
patient-reported outcome |
1 |
|
pci |
1 |
|
peak endocardial acceleration |
1 |
|
pectoralis muscles - blood supply |
1 |
|
pectoralis muscles - surgery |
1 |
|
pennsylvania - epidemiology |
1 |
|
percutaneous coronary |
1 |
|
pericardium - pathology - surgery |
1 |
|
perindopril - therapeutic use |
1 |
|
phlebography |
1 |
|
phosphates - blood |
1 |
|
physician feedback |
1 |
|
plastic ingestion |
1 |
|
platelet activation |
1 |
|
platelet aggregation - drug effects |
1 |
|
platelet aggregation inhibitors - administration & dosage - therapeutic use |
1 |
|
platelet aggregation inhibitors - pharmacology |
1 |
|
platelet factor 4 - analysis |
1 |
|
platelets |
1 |
|
postoperative care |
1 |
|
posture |
1 |
|
potassium - blood |
1 |
|
practice guidelines as topic |
1 |
|
prasugrel |
1 |
|
prevention of premature atrial complexes |
1 |
|
proarrhythmia |
1 |
|
programmed atrial sensitivity |
1 |
|
propafenone - administration & dosage - adverse effects - blood - therapeutic use |
1 |
|
prosthesis design |
1 |
|
protein kinase c - metabolism - physiology |
1 |
|
pulmonary edema - chemically induced - drug therapy |
1 |
|
pulmonary vein |
1 |
|
pulmonary vein isolation |
1 |
|
pulmonary veins |
1 |
|
pulmonary veins - abnormalities - surgery |
1 |
|
pulmonary veins - pathology - surgery |
1 |
|
pulmonary veins - physiology |
1 |
|
pulmonary veins - physiopathology - radiography - surgery |
1 |
|
pulmonary veins - physiopathology - surgery |
1 |
|
pulmonary veins - radiography |
1 |
|
pulmonary veins - radiography - surgery |
1 |
|
pulse - methods |
1 |
|
punctures |
1 |
|
pyridines - administration and dosage |
1 |
|
pyrroles - administration & dosage - adverse effects - therapeutic use |
1 |
|
quadripolar lead |
1 |
|
quality indicators |
1 |
|
quality of care and outcomes |
1 |
|
quinidine - administration & dosage - adverse effects - blood - therapeutic use |
1 |
|
radial artery |
1 |
|
radial artery - physiopathology |
1 |
|
radiofrequency ablation |
1 |
|
radiofrequency catheter ablation |
1 |
|
radiographic image enhancement - methods |
1 |
|
radiography, thoracic |
1 |
|
radionuclide ventriculography |
1 |
|
random forest |
1 |
|
randomized controlled trials as topic |
1 |
|
rate-adaptive pacing |
1 |
|
real-world evidence |
1 |
|
reference values |
1 |
|
refractory period, electrophysiological |
1 |
|
regional blood flow |
1 |
|
reimbursement |
1 |
|
reimbursement mechanisms |
1 |
|
remediation |
1 |
|
remission induction |
1 |
|
remodelling |
1 |
|
remote magnetic navigation |
1 |
|
reproducibility of results |
1 |
|
rest |
1 |
|
retinal diseases - blood - diagnosis - epidemiology - etiology |
1 |
|
retinal vessels - pathology |
1 |
|
retreatment |
1 |
|
rhabdomyolysis - etiology - metabolism |
1 |
|
rheumatic heart disease - blood - complications - ultrasonography |
1 |
|
rhythm control |
1 |
|
right atrium |
1 |
|
right ventricle |
1 |
|
right ventricular infarction |
1 |
|
right ventricular outflow tract |
1 |
|
risk assessment - methods |
1 |
|
risk stratification |
1 |
|
sampling studies |
1 |
|
sensitivity |
1 |
|
sensitivity and specificity |
1 |
|
sensor |
1 |
|
sensory thresholds |
1 |
|
sex characteristics |
1 |
|
shock |
1 |
|
sick sinus syndrome |
1 |
|
sick sinus syndrome - complications - therapy |
1 |
|
sick sinus syndrome - physiopathology - therapy |
1 |
|
sick sinus syndrome - therapy - ultrasonography |
1 |
|
sickness impact profile |
1 |
|
signal transduction - physiology |
1 |
|
single lead ddd pacing |
1 |
|
single pass lead |
1 |
|
sinoatrial node - physiopathology |
1 |
|
sirolimus |
1 |
|
site of atrial pacing |
1 |
|
smad3 |
1 |
|
smad3 protein - deficiency - genetics - physiology |
1 |
|
sodium - blood |
1 |
|
software |
1 |
|
somatic cell reprogramming |
1 |
|
sotalol |
1 |
|
sotalol - administration & dosage |
1 |
|
sotalol - pharmacology - therapeutic use |
1 |
|
sotalol - therapeutic use |
1 |
|
south asia |
1 |
|
statistics as topic |
1 |
|
statistics, nonparametric |
1 |
|
stem cells - cytology |
1 |
|
stent |
1 |
|
stroke - epidemiology |
1 |
|
stroke - epidemiology - etiology - prevention and control |
1 |
|
stroke - etiology - prevention and control |
1 |
|
stroke, machine learning |
1 |
|
subclavian vein |
1 |
|
supraventricular arrhythmia |
1 |
|
supraventricular tachycardia |
1 |
|
surgery, computer-assisted - instrumentation - methods |
1 |
|
survival rate |
1 |
|
switching |
1 |
|
syncope |
1 |
|
systole |
1 |
|
systole - physiology |
1 |
|
tachycardia - diagnosis - therapy |
1 |
|
tachycardia - physiopathology - surgery |
1 |
|
tachycardia, atrioventricular nodal reentry - physiopathology - surgery |
1 |
|
tachycardia, atrioventricular nodal reentry - surgery |
1 |
|
tachycardia, ectopic atrial - diagnosis - pathology - surgery |
1 |
|
tachycardia, paroxysmal - complications - drug therapy - therapy |
1 |
|
tachycardia, paroxysmal - diagnosis - physiopathology - therapy |
1 |
|
tachycardia, paroxysmal - physiopathology - therapy |
1 |
|
tachycardia, paroxysmal - radiography - therapy |
1 |
|
tachycardia, sinus - etiology - physiopathology |
1 |
|
tachycardia, sinus - physiopathology - surgery |
1 |
|
tachycardia, supraventricular - diagnosis - surgery |
1 |
|
tachycardia, supraventricular - surgery |
1 |
|
temperature |
1 |
|
temperature monitoring |
1 |
|
tgf-β |
1 |
|
thallium radioisotopes - diagnostic use |
1 |
|
therapy, computer-assisted - methods |
1 |
|
thiazepines - metabolism - pharmacology |
1 |
|
thiazoles - administration and dosage |
1 |
|
threshold |
1 |
|
thrombectomy |
1 |
|
thromboembolism |
1 |
|
thromboembolism - epidemiology - etiology |
1 |
|
thromboembolism - etiology |
1 |
|
thromboembolism - etiology - prevention & control |
1 |
|
thrombolysis |
1 |
|
thrombolytic therapy - methods |
1 |
|
thrombosis - prevention & control |
1 |
|
ticagrelor |
1 |
|
ticlopidine - administration & dosage - analogs & derivatives |
1 |
|
ticlopidine - analogs & derivatives - pharmacology |
1 |
|
tissue doppler echocardiography |
1 |
|
tni |
1 |
|
toxicity |
1 |
|
transluminal |
1 |
|
transvenous atrial defibrillation |
1 |
|
transvenous defibrillation |
1 |
|
treatment failure |
1 |
|
treatment refusal |
1 |
|
troponin i |
1 |
|
tumor necrosis factor-alpha - metabolism |
1 |
|
ultrasonics |
1 |
|
ultrasonography, interventional - instrumentation |
1 |
|
ultrasound energy |
1 |
|
undersensing |
1 |
|
urinary cells |
1 |
|
urine |
1 |
|
vasodilator agents - diagnostic use |
1 |
|
vasovagal syndrome |
1 |
|
vena cava abnormalities |
1 |
|
vena cava, inferior - abnormalities |
1 |
|
vena cava, superior - abnormalities - surgery |
1 |
|
venography |
1 |
|
venous cutdown |
1 |
|
ventricular dysfunction, left - complications - therapy |
1 |
|
ventricular dysfunction, left - etiology |
1 |
|
ventricular dysfunction, left - etiology - prevention & control |
1 |
|
ventricular dysfunction, right - complications - therapy |
1 |
|
ventricular dysfunction, right - etiology - prevention & control |
1 |
|
ventricular fibrillation - complications - radiography |
1 |
|
ventricular outflow obstruction - complications - diagnosis - surgery |
1 |
|
ventricular outflow obstruction - etiology - radiography |
1 |
|
ventricular premature complexes - diagnosis - etiology - surgery |
1 |
|
ventricular premature complexes - diagnosis - therapy |
1 |
|
ventricular premature contraction |
1 |
|
ventricular remodeling - drug effects - genetics - physiology |
1 |
|
ventricular synchronization |
1 |
|
verapamil |
1 |
|
verapamil - pharmacology |
1 |
|
verapamil - therapeutic use |
1 |
|
walking - physiology |
1 |
|
warfarin - therapeutic use |
1 |
|
wave reflection |
1 |
|
wolff-parkinson-white syndrome - diagnosis - physiopathology - surgery |
1 |
|
wolff-parkinson-white syndrome - surgery |
1 |
|
young adult |
1 |
|
传感器 |
1 |
|
心房颤动 |
1 |
|
窦房结功能不良 |
1 |
|
起搏频率 |
1 |
|
频率适应性 |
1 |
